DE69004837D1 - Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel. - Google Patents

Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel.

Info

Publication number: DE69004837D1
Authority: DE; Germany
Prior art keywords: medicaments; acid; treatment; effective; production
Prior art date: 1989-03-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE90105095T

Other languages

English (en)

Other versions

DE69004837T2 (de

Inventor

Grazie Cristina Le

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

KNOLL-RAVIZZA FARMACEUTICI S.P.A., CAMPOVERDE DI A

Original Assignee

Bioresearch SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-22

Filing date

1990-03-19

Publication date

1994-01-13

1990-03-19 Application filed by Bioresearch SRL filed Critical Bioresearch SRL

1994-01-13 Application granted granted Critical

1994-01-13 Publication of DE69004837D1 publication Critical patent/DE69004837D1/de

1994-04-07 Publication of DE69004837T2 publication Critical patent/DE69004837T2/de

2010-03-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

DE90105095T 1989-03-22 1990-03-19 Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel. Expired - Lifetime DE69004837T2 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT8919867A IT1229203B (it)	1989-03-22	1989-03-22	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.

Publications (2)

Publication Number	Publication Date
DE69004837D1 true DE69004837D1 (de)	1994-01-13
DE69004837T2 DE69004837T2 (de)	1994-04-07

Family

ID=11161918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE90105095T Expired - Lifetime DE69004837T2 (de)	1989-03-22	1990-03-19	Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel.

Country Status (11)

Country	Link
US (1)	US5059595A (de)
EP (1)	EP0388827B1 (de)
JP (1)	JPH0791190B2 (de)
AT (1)	ATE97809T1 (de)
AU (1)	AU637086B2 (de)
CA (1)	CA2012876C (de)
DE (1)	DE69004837T2 (de)
DK (1)	DK0388827T3 (de)
ES (1)	ES2062141T3 (de)
IT (1)	IT1229203B (de)
ZA (1)	ZA902153B (de)

Families Citing this family (896)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1229517B (it) *	1989-01-31	1991-09-03	Bioresearch Spa	Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
IT1243859B (it) *	1990-10-23	1994-06-28	Bioresearch Spa	Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids.
US6429221B1 (en) *	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US5660835A (en) *	1995-02-24	1997-08-26	East Carolina University	Method of treating adenosine depletion
US20020032160A1 (en) *	1995-02-24	2002-03-14	Nyce Jonathan W.	Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US6858589B2 (en)	1996-01-25	2005-02-22	Pharmacy And Therapeutic Advisory Consultancy Pty Ltd	Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
AU722050B2 (en)	1996-01-31	2000-07-20	South Alabama Medical Science Foundation	Food and vitamin preparations containing the natural isomer of reduced folates
EP0918746B1 (de) *	1996-08-12	2003-04-09	Celgene Corporation	Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
CH693255A5 (de) *	1997-06-13	2003-05-15	Eprova Ag	Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
HUP0102026A3 (en)	1998-06-15	2002-12-28	Sepracor Inc Marlborough	Use of optically pure (-) norcisapride for producing pharmaceutical compositions suitable for treating apnea, bulimis, and other disorders
HUP0102203A3 (en) *	1998-06-15	2001-12-28	Sepracor Inc Marlborough	Use of optically pure(+)-norcisapride for producing pharmaceutical compositions suitable for treating apnea, bulimia and other disorders
US6331571B1 (en)	1998-08-24	2001-12-18	Sepracor, Inc.	Methods of treating and preventing attention deficit disorders
US6339106B1 (en)	1999-08-11	2002-01-15	Sepracor, Inc.	Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) *	1998-08-24	2005-12-13	Sepracor Inc.	Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) *	1999-08-11	2002-11-05	Sepracor, Inc.	Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
ATE235244T1 (de) *	1998-10-30	2003-04-15	Merck Patent Gmbh	Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
US6342533B1 (en)	1998-12-01	2002-01-29	Sepracor, Inc.	Derivatives of (−)-venlafaxine and methods of preparing and using the same
EP1139913A4 (de) *	1999-01-05	2002-09-11	Univ East Carolina	Zusammensetzungen und substanzen sowie deren anwendung als nociceptische, antianxiolytische und anabolische wirkstoffe
WO2000051582A2 (en)	1999-03-01	2000-09-08	Sepracor Inc.	Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
US6342496B1 (en)	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
US6353005B1 (en)	1999-03-02	2002-03-05	Sepracor, Inc.	Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en)	1999-03-02	2002-03-26	Sepracor Inc.	Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6410052B1 (en)	1999-03-30	2002-06-25	Purdue Research Foundation	Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
US6428818B1 (en)	1999-03-30	2002-08-06	Purdue Research Foundation	Tea catechin formulations and processes for making same
CZ20013607A3 (cs)	1999-04-06	2002-06-12	Sepracor Inc.	Farmaceutický prostředek
US6951873B1 (en)	1999-04-27	2005-10-04	Pfizer Inc.	Methods for treating age-related behavioral disorders in companion animals
US6399826B1 (en)	1999-08-11	2002-06-04	Sepracor Inc.	Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
DE60026146T2 (de)	1999-09-03	2006-08-17	Apbi Holdings, Llc	Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
ATE364689T1 (de)	1999-11-18	2007-07-15	Dendreon Corp	Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
US7182953B2 (en)	1999-12-15	2007-02-27	Celgene Corporation	Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US7700341B2 (en) *	2000-02-03	2010-04-20	Dendreon Corporation	Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
KR20030003708A (ko) *	2000-03-31	2003-01-10	셀진 코포레이션	시클로옥시게나제-2 활성의 저해
DE10022856A1 (de) *	2000-05-10	2001-11-15	Basf Ag	Therapeutische Kombination von Liponsäure und C1-Donoren zur Behandlung von Störungen des Zentralen Nervensystems
US7259152B2 (en)	2000-06-07	2007-08-21	Alfa Wasserman, Inc.	Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US20070208087A1 (en)	2001-11-02	2007-09-06	Sanders Virginia J	Compounds, compositions and methods for the treatment of inflammatory diseases
DE60130799T2 (de) *	2000-11-30	2008-07-17	Children's Medical Center Corp., Boston	Synthese von 4-aminothalidomid enantiomeren
US20030167524A1 (en) *	2000-12-19	2003-09-04	Rooijen Gijs Van	Methods for the production of multimeric protein complexes, and related compositions
WO2002064543A2 (en) *	2001-02-12	2002-08-22	Wyeth	Novel succinate salt of o-desmethyl-venlafaxine
AU2002305052A1 (en)	2001-03-13	2002-09-24	Corvas International, Inc.	Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
JP2004535166A (ja)	2001-03-22	2004-11-25	デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー	セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
EP1379637A4 (de)	2001-03-27	2005-04-06	Dendreon Corp	Transmembran-serinprotease 9 codierende nukleinsäuremoleküle, die codierten polypeptide sowie darauf beruhende verfahren
US6610887B2 (en)	2001-04-13	2003-08-26	Sepracor Inc.	Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20050070487A1 (en) *	2001-04-24	2005-03-31	Nyce Jonathan W.	Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002303427A1 (en) *	2001-04-24	2002-11-05	East Carolina University	Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
JP2005506832A (ja)	2001-05-14	2005-03-10	デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー	トランスメンブランセリンプロテアーゼ１０をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
AU2002346065A1 (en) *	2001-07-05	2003-01-21	Marantech Holding, Llc	Methods of using electron active compounds for managing conditions afflicting mammals
US20030087963A1 (en)	2001-09-13	2003-05-08	Senanayake Chris H.	Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
US20030134794A1 (en) *	2001-11-20	2003-07-17	Madison Edwin L.	Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
CA2469306A1 (en)	2001-12-05	2003-06-19	Baylor College Of Medicine	Methods and compositions for control of bone formation via modulation of sympathetic tone
US20030181416A1 (en) *	2002-01-10	2003-09-25	Comper Wayne D.	Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20040009953A1 (en) *	2002-01-10	2004-01-15	Comper Wayne D.	Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
AU2003212882A1 (en)	2002-02-01	2003-09-02	Euro-Celtique S.A.	2 - piperazine - pyridines useful for treating pain
US7927613B2 (en)	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
US7446107B2 (en) *	2002-02-15	2008-11-04	Transform Pharmaceuticals, Inc.	Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
CA2477923C (en)	2002-03-01	2021-02-23	University Of South Florida	Multiple-component solid phases containing at least one active pharmaceutical ingredient
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7205413B2 (en) *	2002-05-03	2007-04-17	Transform Pharmaceuticals, Inc.	Solvates and polymorphs of ritonavir and methods of making and using the same
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
NZ549175A (en)	2002-05-17	2007-12-21	Celgene Corp	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
US20100129363A1 (en) *	2002-05-17	2010-05-27	Zeldis Jerome B	Methods and compositions using pde4 inhibitors for the treatment and management of cancers
CA2486141A1 (en)	2002-05-17	2003-11-27	Celgene Corporation	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
USRE48890E1 (en)	2002-05-17	2022-01-11	Celgene Corporation	Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20040001801A1 (en) *	2002-05-23	2004-01-01	Corvas International, Inc.	Conjugates activated by cell surface proteases and therapeutic uses thereof
US20070059356A1 (en) *	2002-05-31	2007-03-15	Almarsson Oern	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US6995168B2 (en)	2002-05-31	2006-02-07	Euro-Celtique S.A.	Triazaspiro compounds useful for treating or preventing pain
US8829198B2 (en)	2007-10-31	2014-09-09	Proteotech Inc	Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
PT1511710E (pt)	2002-05-31	2014-02-26	Proteotech Inc	Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
AU2003243354A1 (en) *	2002-05-31	2003-12-19	Transform Pharmaceuticals, Inc.	Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US7405207B2 (en) *	2002-06-17	2008-07-29	Epigenesis Pharmaceuticals, Inc.	Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
MXPA04012720A (es) *	2002-06-17	2007-03-23	Epigenesis Pharmaceuticals Llc	Formulaciones de deshidroepiandrosterona para nebulizador y metodos para tratar asma o enfermedad pulmonar obstructiva cronica utilizando composiciones de la misma.
MXPA05000232A (es) *	2002-06-21	2005-06-17	Transform Pharmaceuticals Inc	Composiciones farmaceuticas con disolucion mejorada.
WO2004009558A2 (en)	2002-07-24	2004-01-29	Ptc Therapeutics, Inc.	Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
CA2500118C (en)	2002-09-25	2011-04-12	Euro-Celtique S.A.	N-substituted hydromorphones and the use thereof
AU2003276988B2 (en) *	2002-09-27	2009-11-05	Bioenvision, Inc.	Methods and compositions for the treatment of autoimmune disorders using clofarabine
EP1551386A4 (de) *	2002-09-27	2009-03-25	Bioenvision Inc	Verfahren und zusammensetzungen zur behandlung von lupus mit clofarabin
CA2499549C (en) *	2002-10-11	2012-01-24	Proteotech, Inc.	Isolation, purification and synthesis of procyanidin b2 and uses thereof
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
ZA200503024B (en) *	2002-10-15	2006-11-29	Celgene Corp	Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
EP1900369A1 (de)	2002-10-15	2008-03-19	Celgene Corporation	Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
US8404717B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes using lenalidomide
US20040087558A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7776907B2 (en) *	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US7563810B2 (en)	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CA2505003A1 (en) *	2002-11-06	2004-05-27	Celgene Corporation	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
KR100923173B1 (ko)	2002-11-06	2009-10-22	셀진 코포레이션	암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨억제 약물의 사용 방법 및 그 조성물
CA2506232A1 (en) *	2002-11-18	2004-06-03	Celgene Corporation	Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
AU2003294312A1 (en) *	2002-11-18	2004-07-09	Celgene Corporation	Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US7202259B2 (en) *	2002-11-18	2007-04-10	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
US6864251B2 (en)	2002-12-03	2005-03-08	Vela Pharmaceuticals, Inc.	Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
EP2298874A1 (de)	2002-12-16	2011-03-23	Halozyme, Inc.	Humanes Chondrotinaseglykoprotein (CHASEGP), Verfahren zu dessen Herstellung und pharmazeutische Zusammensetzungen, die dieses umfassen
US7582635B2 (en)	2002-12-24	2009-09-01	Purdue Pharma, L.P.	Therapeutic agents useful for treating pain
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
EP2339328A3 (de)	2002-12-30	2011-07-13	Transform Pharmaceuticals, Inc.	Pharmazeutische kokristallisierte Celecoxib-Zusammensetzungen
AU2003272270A1 (en)	2003-02-28	2004-09-28	The Regents Of The University Of Michigan	Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP2405015B1 (de)	2003-03-05	2016-01-06	Halozyme, Inc.	Lösliches Hyaluronidaseglykoprotein (sHASEGP), Verfahren zu dessen Herstellung, Verwendungen und pharmazeutische Zusammensetzungen, die dieses umfassen
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) *	2003-03-05	2009-05-14	Delfmems	Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20040214893A1 (en) *	2003-04-11	2004-10-28	Matthew Peterson	Gabapentin compositions
SI3632902T1 (sl)	2003-04-11	2022-01-31	Ptc Therapeutics, Inc.	Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni
CA2525969A1 (en) *	2003-05-16	2005-02-24	Receptor Biologix, Inc.	Intron fusion proteins, and methods of identifying and using same
JP2007502329A (ja) *	2003-05-23	2007-02-08	トランスフォーム・ファーマシューティカルズ・インコーポレイテッド	セルトラリン組成物
US8916598B2 (en)	2003-05-30	2014-12-23	Proteotech Inc	Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20100331380A1 (en) *	2009-06-29	2010-12-30	Esposito Luke A	Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US7438903B2 (en) *	2003-06-06	2008-10-21	Nbty, Inc.	Methods and compositions that enhance bioavailability of coenzyme-Q10
AR044688A1 (es) *	2003-06-12	2005-09-21	Euro Celtique Sa	Agentes terapeuticos utiles para el tratamiento del dolor
PL1641775T3 (pl) *	2003-07-03	2009-07-31	Euro Celtique Sa	Pochodne 2-pirydynoalkin użyteczne do leczenia bólu
US20050009782A1 (en) *	2003-07-09	2005-01-13	Comper Wayne D.	Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
NZ545447A (en)	2003-07-23	2010-03-26	Synta Pharmaceuticals Corp	Compounds for inflammation and immune-related uses
EP1867644B1 (de)	2003-07-24	2009-05-20	Euro-Celtique S.A.	Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
EP1648878B9 (de) *	2003-07-24	2011-03-16	Euro-Celtique S.A.	Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
AU2004259358B2 (en) *	2003-07-24	2008-03-20	Euro-Celtique S.A.	Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
US20050026880A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) *	2003-07-31	2005-02-17	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) *	2003-07-31	2009-11-19	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) *	2003-07-31	2009-10-22	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) *	2003-07-31	2009-11-19	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) *	2003-07-31	2005-02-24	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) *	2003-07-31	2005-04-21	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) *	2003-07-31	2005-05-12	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) *	2003-07-31	2005-05-26	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) *	2003-07-31	2009-11-05	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) *	2003-07-31	2009-12-03	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
MXPA06001331A (es) *	2003-08-01	2006-05-04	Euro Celtique Sa	Agentes terapeuticos utiles para el tratamiento del dolor.
JP4614139B2 (ja) *	2003-08-12	2011-01-19	キョンドンファームカンパニーリミテッド	塩酸タムスロシン徐放性錠剤の製造方法、およびそれからなる塩酸タムスロシン徐放性錠剤
WO2005020954A2 (en) *	2003-09-03	2005-03-10	Agi Therapeutics Limited	Proton pump inhibitor formulations, and methods of preparing and using such formulations
UA83504C2 (en)	2003-09-04	2008-07-25	Селджин Корпорейшн	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
PL1664016T3 (pl) *	2003-09-22	2009-04-30	Euro Celtique Sa	Środki terapeutyczne przydatne do leczenia bólu
CA2537010A1 (en) *	2003-09-22	2005-04-07	Euro-Celtique S.A.	Phenyl - carboxamide compounds useful for treating pain
US7612096B2 (en) *	2003-10-23	2009-11-03	Celgene Corporation	Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050113410A1 (en) *	2003-11-03	2005-05-26	Mark Tawa	Pharmaceutical salts of zafirlukast
US20070208057A1 (en) *	2003-11-06	2007-09-06	Zeldis Jerome B	Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
US7470435B2 (en) *	2003-11-17	2008-12-30	Andrx Pharmaceuticals, Llc	Extended release venlafaxine formulation
EP2428516A1 (de)	2003-11-19	2012-03-14	Metabasis Therapeutics, Inc.	Neue Phosphor enthaltende Thyromimetika
AU2004293443A1 (en)	2003-11-19	2005-06-09	Signal Pharmaceuticals, Llc.	Indazole Compounds and methods of use thereof as protein kinase inhibitors
DE602004019576D1 (de) *	2003-12-30	2009-04-02	Euro Celtique Sa	Zur behandlung von schmerzen geeignete piperazine
EP2292213A1 (de)	2004-02-06	2011-03-09	Cephalon, Inc.	Armodafinil Polymorph enthaltende Zusammensetzungen
US20060003001A1 (en) *	2004-02-11	2006-01-05	John Devane	Chronotherapeutic compositions and methods of their use
EP1720540B1 (de)	2004-02-18	2008-06-11	GPC Biotech AG	Satraplatin zur behandlung von resistenten oder refrkatären tumoren
EP1737453A4 (de)	2004-03-22	2008-11-26	Celgene Corp	Verfahren zur verwendung immunmodulatorischer verbindungen und diese enthaltende zusammensetzungen zur behandlung und versorgung von hautkrankheiten oder störungen
WO2005092065A2 (en) *	2004-03-25	2005-10-06	Transform Pharmaceuticals, Inc.	Novel tricyclic compounds and related methods of treatment
JP2007532642A (ja) *	2004-04-14	2007-11-15	セルジーン・コーポレーション	脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
EA014429B1 (ru) *	2004-04-14	2010-12-30	Селджин Корпорейшн	Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов, и способы с их использованием
KR20070007945A (ko) *	2004-04-23	2007-01-16	셀진 코포레이션	폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물
US7351739B2 (en) *	2004-04-30	2008-04-01	Wellgen, Inc.	Bioactive compounds and methods of uses thereof
US7803366B2 (en) *	2004-05-07	2010-09-28	Nbty, Inc.	Methods and compositions that enhance bioavailability of coenzyme-Q10
AU2005245896A1 (en) *	2004-05-14	2005-12-01	Receptor Biologix, Inc.	Cell surface receptor isoforms and methods of identifying and using the same
US7671093B2 (en)	2004-05-28	2010-03-02	Transform Pharmaceuticals, Inc.	Mixed co-crystals and pharmaceutical compositions comprising the same
WO2005120584A2 (en) *	2004-06-03	2005-12-22	The Trustees Of Columbia University In The City Of New York	Radiolabeled arylsulfonyl compounds and uses thereof
JP5017103B2 (ja) *	2004-06-17	2012-09-05	トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド	薬剤共結晶組成物および関連した使用方法
US20080126195A1 (en)	2004-07-22	2008-05-29	Ritter Andrew J	Methods and Compositions for Treating Lactose Intolerance
US20060024384A1 (en) *	2004-07-29	2006-02-02	Giordano John A	Compositions and methods for nutrition supplementation
US20060024409A1 (en) *	2004-07-29	2006-02-02	Everett Laboratories, Inc.	Compositions and methods for nutrition supplementation
US20090042979A1 (en) *	2004-08-06	2009-02-12	Transform Pharmaceuticals Inc.	Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
CA2573316A1 (en) *	2004-08-06	2006-02-16	Transform Pharmaceuticals, Inc.	Novel fenofibrate formulations and related methods of treatment
NZ552389A (en) *	2004-08-06	2009-05-31	Transform Pharmaceuticals Inc	Statin pharmaceutical compositions and related methods of treatment
NZ584773A (en)	2004-09-17	2012-07-27	Whitehead Biomedical Inst	Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
JP2008513508A (ja) *	2004-09-21	2008-05-01	シンタファーマシューティカルズコーポレーション	炎症及び免疫に関連する用途に用いる化合物
EP1645276A1 (de) *	2004-10-08	2006-04-12	Wageningen Centre for Food Sciences	Behandlung von neurodegenerativen Erkrankungen
KR20070085454A (ko) *	2004-10-28	2007-08-27	셀진 코포레이션	중추신경계 손상의 치료 및 관리를 위하여 ｐｄｅ４조절제를 사용하는 방법 및 조성물
CN103554042B (zh)	2004-11-18	2016-08-10	Synta医药公司	调节hsp90活性的三唑化合物
ES2401285T3 (es)	2004-12-16	2013-04-18	The Regents Of The University Of California	Fármacos con el pulmón como diana
ES2525567T3 (es)	2004-12-17	2014-12-26	Anadys Pharmaceuticals, Inc.	Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
EP1674457B1 (de)	2004-12-23	2009-06-03	GPC Biotech AG	Quadratsäurederivate mit antiproliferativer Wirkung
US20060160783A1 (en) *	2004-12-30	2006-07-20	Transform Pharmaceuticals, Inc.	Novel omeprazole forms and related methods
NZ556546A (en) *	2005-01-07	2011-02-25	Synta Pharmaceuticals Corp	Compounds for inflammation and immune-related uses
ZA200707125B (en)	2005-01-25	2008-11-26	Synta Pharmaceuticals Corp	Compounds for inflammation and immune-related uses
CN101189249B (zh)	2005-04-01	2013-04-17	加利福尼亚大学董事会	膦酰基-戊-2-烯-1-基核苷和类似物
US20090156545A1 (en) *	2005-04-01	2009-06-18	Hostetler Karl Y	Substituted Phosphate Esters of Nucleoside Phosphonates
JP2008539731A (ja)	2005-05-02	2008-11-20	コールドスプリングハーバーラボラトリー	癌の診断及び治療のための組成物及び方法
WO2006119510A2 (en) *	2005-05-04	2006-11-09	Receptor Biologix, Inc.	Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
US20070041944A1 (en) *	2005-05-05	2007-02-22	The Trustees Of Columbia University In The City Of New York	Treating tumors by ENH dislocation of ID proteins
US20090170769A1 (en) *	2005-05-13	2009-07-02	Pei Jin	Cell surface receptor isoforms and methods of identifying and using the same
US20060270707A1 (en) *	2005-05-24	2006-11-30	Zeldis Jerome B	Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20100098640A1 (en) *	2005-06-20	2010-04-22	Cohen Seth M	Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20070054868A1 (en) *	2005-06-20	2007-03-08	The Trustees Of Columbia University In The City Of New York	Synergistic polyphenol compounds, compositions thereof, and uses thereof
AU2006262096B2 (en) *	2005-06-21	2012-11-01	Children's Hospital & Research Center At Oakland	Methods and compositions containing natural folates for protecting against radiation damage
MX2008000249A (es) *	2005-07-06	2008-03-18	Sepracor Inc	Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
JP2009505955A (ja)	2005-07-22	2009-02-12	アムゲンインコーポレイティッド	アニリンスルホンアミド誘導体およびそれらの使用
US20080058282A1 (en)	2005-08-30	2008-03-06	Fallon Joan M	Use of lactulose in the treatment of autism
MX2008002765A (es)	2005-08-31	2008-04-07	Celgene Corp	Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
US20080138295A1 (en) *	2005-09-12	2008-06-12	Celgene Coporation	Bechet's disease using cyclopropyl-N-carboxamide
US20070066512A1 (en)	2005-09-12	2007-03-22	Dominique Verhelle	Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US8492428B2 (en) *	2005-09-20	2013-07-23	Mayo Foundation For Medical Education And Research	Small-molecule botulinum toxin inhibitors
EP2298770A1 (de)	2005-11-03	2011-03-23	ChemBridge Corporation	Heterocyclische Verbindungen als TrkA Modulatoren
WO2007058776A2 (en) *	2005-11-10	2007-05-24	Receptor Biologix, Inc.	Hepatocyte growth factor intron fusion proteins
EP1959936A2 (de)	2005-11-10	2008-08-27	Circ Pharma Research and Development Limited	Einmal pro tag erfolgende verabreichung von wirkstoffen für das zentrale nervensystem
CN101312964A (zh)	2005-11-21	2008-11-26	普渡制药公司	4-噁二唑基哌啶化合物及其用途
US8138361B2 (en) *	2005-12-28	2012-03-20	The Trustees Of The University Of Pennsylvania	C-10 carbamates of taxanes
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
CA2841386A1 (en)	2005-12-30	2007-07-12	Zensun (Shanghai) Science & Technology Limited	Extended release of neuregulin for improved cardiac function
CA2640091A1 (en)	2006-01-25	2007-08-02	Synta Pharmaceuticals Corp.	Vinyl-phenyl derivatives for inflammation and immune-related uses
EP1983980A4 (de) *	2006-01-25	2010-05-05	Synta Pharmaceuticals Corp	Thiazol- und thiadiazol-verbindungen für verwendungen in verbindung mit entzündung und immunität
WO2007087442A2 (en)	2006-01-25	2007-08-02	Synta Pharmaceuticals Corp.	Substituted biaryl compounds for inflammation and immune-related uses
WO2007089904A2 (en)	2006-01-31	2007-08-09	Synta Pharmaceuticals Corp.	Pyridylphenyl compounds for inflammation and immune-related uses
US7518017B2 (en)	2006-02-17	2009-04-14	Idexx Laboratories	Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
WO2007106468A2 (en) *	2006-03-13	2007-09-20	Encysive Pharmaceuticals, Inc.	Formulations of sitaxsentan sodium
US20070232671A1 (en) *	2006-03-13	2007-10-04	Given Bruce D	Methods and compositions for treatment of diastolic heart failure
AU2007225088B2 (en)	2006-03-13	2012-09-13	Kyorin Pharmaceutical Co., Ltd	Aminoquinolones as GSK-3 inhibitors
EP2007373A4 (de) *	2006-03-29	2012-12-19	Foldrx Pharmaceuticals Inc	Hemmung der alpha-synuclein-toxizität
TW200808695A (en) *	2006-06-08	2008-02-16	Amgen Inc	Benzamide derivatives and uses related thereto
DE602007008237D1 (de) *	2006-06-08	2010-09-16	Amgen Inc	Benzamidderivate und assoziierte verwendungen
US20100055093A1 (en) *	2006-06-12	2010-03-04	Receptor Biologix Inc.	Pan-cell surface receptor-specific therapeutics
ATE496924T1 (de)	2006-06-22	2011-02-15	Anadys Pharmaceuticals Inc	Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
US20080026061A1 (en) *	2006-06-22	2008-01-31	Reichwein John F	Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
CN101501039B (zh)	2006-06-22	2012-02-22	安那迪斯药品股份有限公司	吡咯并[1,2-b]哒嗪酮化合物
JP4546578B2 (ja)	2006-07-05	2010-09-15	カタリスト・バイオサイエンシーズ・インコーポレイテッド	プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ
WO2008008373A2 (en)	2006-07-11	2008-01-17	Arubor Corp	Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
DE602007012881D1 (en)	2006-07-18	2011-04-14	Anadys Pharmaceuticals Inc	Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
CL2007002218A1 (es)	2006-08-03	2008-03-14	Celgene Corp Soc Organizada Ba	Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
WO2008029300A2 (en) *	2006-08-04	2008-03-13	Agi Therapeutics Research Limited	Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
US8063225B2 (en)	2006-08-14	2011-11-22	Chembridge Corporation	Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
US20080038410A1 (en) *	2006-08-18	2008-02-14	Everett Laboratories, Inc.	Compositions and methods for nutrition supplementation
US9114133B2 (en)	2006-08-25	2015-08-25	U.S. Dept. Of Veterans Affairs	Method of improving diastolic dysfunction
NZ575061A (en)	2006-08-30	2011-10-28	Celgene Corp	5-substituted isoindoline compounds
US8877780B2 (en)	2006-08-30	2014-11-04	Celgene Corporation	5-substituted isoindoline compounds
US7879846B2 (en)	2006-09-21	2011-02-01	Kyorin Pharmaceutical Co.., Ltd.	Serine hydrolase inhibitors
US8779154B2 (en)	2006-09-26	2014-07-15	Qinglin Che	Fused ring compounds for inflammation and immune-related uses
NZ575830A (en)	2006-09-26	2012-03-30	Celgene Corp	5-substituted quinazolinone derivatives as antitumor agents
EP2124556B1 (de)	2006-10-09	2014-09-03	Charleston Laboratories, Inc.	Pharmazeutische zusammensetzungen
EP1914234A1 (de) *	2006-10-16	2008-04-23	GPC Biotech Inc.	Pyrido[2,3-d]pyrimidinen und ihre Verwendung als kinase Inhibitoren
DE602007013440D1 (de)	2006-10-19	2011-05-05	Auspex Pharmaceuticals Inc	Substituierte indole
EP2617423A1 (de)	2006-10-19	2013-07-24	Genzyme Corporation	Purinderivate zur Behandlung zystischer Erkrankungen
WO2008057604A2 (en) *	2006-11-08	2008-05-15	The Regents Of The University Of California	Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
EP2086326B1 (de)	2006-11-13	2014-01-08	Synta Pharmaceuticals Corp.	Cyclohexenyl-aryl-verbindungen gegen entzündungen und immunspezifische erkrankungen
EP2091527B1 (de)	2006-12-13	2016-03-23	Temple University - Of The Commonwealth System of Higher Education	Sulfid-, sulfoxid- und sulfon-chalcon-analoge, derivate davon und therapeutische anwendungen davon
CA2671766A1 (en) *	2006-12-22	2008-07-03	Encysive Pharmaceuticals, Inc.	Modulators of c3a receptor and methods of use thereof
AU2007343726A1 (en) *	2006-12-26	2008-07-24	Amgen Inc.	N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
KR101227072B1 (ko) *	2007-01-16	2013-01-29	시오노기세이야쿠가부시키가이샤	Ｏｒｌ-1 리간드로서의 헤테로시클릭-치환 피페리딘
KR20180099916A (ko)	2007-02-09	2018-09-05	메타베이시스 테라퓨틱스, 인크.	글루카곤 수용체의 길항제
JP5666140B2 (ja)	2007-02-21	2015-02-12	サノヴィオンファーマシューティカルズインコーポレーテッド	（−）−ｏ−デスメチルベンラファキシンを含む固形物およびそれらの使用
DK2144604T3 (da) *	2007-02-28	2011-10-17	Conatus Pharmaceuticals Inc	Fremgangsmåder til behandling af kronisk viral hepatitis C under anvendelse af RO 113-0830
WO2008106167A1 (en) *	2007-02-28	2008-09-04	Conatus Pharmaceuticals, Inc.	Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
SI2125698T1 (sl)	2007-03-15	2016-12-30	Auspex Pharmaceuticals, Inc.	Devterirani d9-venlafaksin
EP2380564B1 (de)	2007-04-04	2014-10-22	Sigmoid Pharma Limited	Orale pharmazeutische Zusammensetzung
EP2061587A1 (de)	2007-04-26	2009-05-27	Sigmoid Pharma Limited	Herstellung mehrerer minikapseln
AU2008243874B2 (en)	2007-04-27	2012-01-19	Purdue Pharma L.P.	TRPV1 antagonists and uses thereof
JP5372913B2 (ja)	2007-04-27	2013-12-18	パーデュー、ファーマ、リミテッド、パートナーシップ	疼痛治療に有効な治療薬
US7892776B2 (en)	2007-05-04	2011-02-22	The Regents Of The University Of California	Screening assay to identify modulators of protein kinase A
EP2019101A1 (de) *	2007-07-26	2009-01-28	GPC Biotech AG	Pyrazol[3,4-d]pyrimidin-4-one nützlich als Kinase-Inhibitor
CN103936605B (zh)	2007-05-31	2017-09-01	赛诺维信制药公司	苯基取代的环烷胺作为一元胺再摄取抑制剂
EP2572712A3 (de)	2007-06-01	2013-11-20	The Trustees Of Princeton University	Behandlung von Virusinfektionen durch Modulation von Hostzellen-Stoffwechselpfaden
US8415294B2 (en) *	2007-06-05	2013-04-09	Arizona Board Of Regents	Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
BRPI0814409A2 (pt) *	2007-07-06	2014-10-14	Nuon Therapeutics Inc	Tratamento de dor neuropática
MX2010000465A (es) *	2007-07-12	2010-08-30	Tragara Pharmaceuticals Inc	Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
WO2009012263A2 (en) *	2007-07-18	2009-01-22	The Trustees Of Columbia University In The City Of New York	Tissue-specific micrornas and compositions and uses thereof
WO2009017831A1 (en)	2007-08-01	2009-02-05	Synta Pharmaceuticals Corp.	Vinyl-aryl derivatives for inflammation and immune-related uses
US8435996B2 (en)	2007-08-01	2013-05-07	Synta Pharmaceuticals Corp.	Heterocycle-aryl compounds for inflammation and immune-related uses
US7893045B2 (en)	2007-08-07	2011-02-22	Celgene Corporation	Methods for treating lymphomas in certain patient populations and screening patients for said therapy
CA2695583A1 (en)	2007-08-13	2009-02-19	Metabasis Therapeutics, Inc.	Novel activators of glucokinase
US20090062242A1 (en) *	2007-08-28	2009-03-05	Agi Therapeutics Plc	Methods and compositions for treating gastrointestinal conditions
NZ582940A (en)	2007-08-31	2013-01-25	Purdue Pharma Lp	Substituted-quinoxaline-type piperidine compounds and the uses thereof
CA2699151A1 (en) *	2007-09-11	2009-03-19	Activx Biosciences, Inc.	Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
MX2010002662A (es)	2007-09-12	2010-04-09	Activx Biosciences Inc	Aminoquinolonas espirociclicas como inhibidores de gsk-3.
US8492395B2 (en)	2007-09-26	2013-07-23	Celgene Corporation	7-substituted quinazolinone compounds and compositions comprising the same
US20090264421A1 (en) *	2007-10-05	2009-10-22	Bible Keith C	Methods and Compositions for Treating Cancer
KR20100082775A (ko) *	2007-10-16	2010-07-19	심포젠 에이/에스	최적화된 ｈｅｒ1 및 ｈｅｒ3 멀티머를 포함하는 조성물 및 그것의 사용 방법
US20110009463A1 (en) *	2007-10-17	2011-01-13	Yuri Karl Petersson	Geranylgeranyl transferase inhibitors and methods of making and using the same
CA2702494A1 (en)	2007-10-19	2009-04-23	The Regents Of The University Of California	Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
US8293513B2 (en)	2007-12-14	2012-10-23	Georgetown University	Histone deacetylase inhibitors
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2240022B1 (de)	2008-01-09	2016-12-28	Charleston Laboratories, Inc.	Oxycodone und Promethazine enthaltende zweischichtige Tabletten
WO2009111611A2 (en) *	2008-03-05	2009-09-11	Proteotech Inc.	Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
TWI395593B (zh)	2008-03-06	2013-05-11	Halozyme Inc	可活化的基質降解酵素之活體內暫時性控制
US8658163B2 (en)	2008-03-13	2014-02-25	Curemark Llc	Compositions and use thereof for treating symptoms of preeclampsia
MY161576A (en)	2008-03-17	2017-04-28	Ambit Biosciences Corp	Quinazoline derivatives as raf kinase modulators and methods of use thereof
US8822500B2 (en)	2008-03-19	2014-09-02	Chembridge Corporation	Tyrosine kinase inhibitors
US9249147B2 (en)	2008-03-19	2016-02-02	Chembridge Corporation	Tyrosine kinase inhibitors
JP5628145B2 (ja)	2008-03-19	2014-11-19	ケムブリッジ・コーポレーション	新規チロシンキナーゼ阻害剤
KR20150038547A (ko)	2008-03-27	2015-04-08	셀진 코포레이션	(+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온을 포함하는 고체 형태, 이의 조성물, 및 이의 용도
EP2687213B1 (de)	2008-03-27	2019-01-23	Celgene Corporation	(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion umfassende feste Formen, Zusammensetzungen daraus und ihre Verwendungszwecke
KR101647932B1 (ko)	2008-04-14	2016-08-11	할로자임, 아이엔씨	히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
US8084025B2 (en)	2008-04-18	2011-12-27	Curemark Llc	Method for the treatment of the symptoms of drug and alcohol addiction
EP2112150B1 (de)	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Verbesserte Raf-Inhibitoren
EP2112152A1 (de)	2008-04-22	2009-10-28	GPC Biotech AG	Dihydropteridinones als Plk-Inhibitoren
WO2009139880A1 (en) *	2008-05-13	2009-11-19	Celgene Corporation	Thioxoisoindoline compounds and compositions and methods of using the same
CA2724594A1 (en) *	2008-05-20	2009-11-26	John R. Wetterau	Niacin and nsaid combination therapy
WO2009158430A1 (en) *	2008-06-25	2009-12-30	Iskandar Bermans S	(6s)-5-methyltetrahydrofolic acid for therapy of tissue injury
EP2318035B1 (de)	2008-07-01	2019-06-12	Curemark, Llc	Verfahren und zusammensetzungen zur behandlung von symptomen von neurologischen und geistesstörungen
TW201004632A (en)	2008-07-02	2010-02-01	Idenix Pharmaceuticals Inc	Compounds and pharmaceutical compositions for the treatment of viral infections
CN102105465B (zh)	2008-07-21	2015-03-11	普渡制药公司	取代的喹喔啉型桥连哌啶化合物及其用途
KR101343395B1 (ko)	2008-07-30	2013-12-19	퍼듀 퍼머 엘피	부프레노르핀 유사체
EP3153501B1 (de)	2008-08-13	2018-11-28	Metabasis Therapeutics, Inc.	Glucagon-antagonisten
WO2010027975A1 (en)	2008-09-04	2010-03-11	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
EP2340254B8 (de)	2008-09-15	2014-05-21	Biovista, Inc.	Zusammensetzungen und verfahren zur behandlung von epilepsie
TW201026693A (en) *	2008-10-01	2010-07-16	Synta Pharmaceuticals Corp	Compounds for inflammation and immune-related uses
EP2346329B1 (de)	2008-10-09	2013-08-21	Anadys Pharmaceuticals, Inc.	Verfahren zur hemmung des hepatitis-c-virus mittels kombination aus einem 5,6-dihydro-1h-pyridin-2-on und einer oder mehreren antiviralen verbindungen
CA2740107A1 (en) *	2008-10-10	2010-04-15	Purdue Research Foundation	Compounds for treatment of alzheimer's disease
US8703962B2 (en) *	2008-10-24	2014-04-22	Purdue Pharma L.P.	Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) *	2008-10-24	2014-06-24	Purdue Pharma L.P.	Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) *	2008-10-24	2013-10-01	Purdue Pharma L.P.	Heterocyclic TRPV1 receptor ligands
PL2358697T3 (pl)	2008-10-29	2016-04-29	Celgene Corp	Związki izoindolinowe do zastosowania w leczeniu raka
WO2010059953A1 (en) *	2008-11-20	2010-05-27	Purdue Research Foundation	Quinazoline inhibitors of bace 1 and methods of using
US8859590B2 (en)	2008-12-05	2014-10-14	Purdue Research Foundation	Inhibitors of BACE1 and methods for treating Alzheimer's disease
PT3037529T (pt)	2008-12-09	2019-05-31	Halozyme Inc	Polipéptidos ph20 estendidos solúveis e suas utilizações
AU2009330355B2 (en)	2008-12-16	2016-06-30	Sunovion Pharmaceuticals Inc.	Triple reuptake inhibitors and methods of their use
JP2012513468A (ja)	2008-12-22	2012-06-14	スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ	癌及び神経変性疾患の治療又は予防方法
US20110306605A1 (en)	2008-12-22	2011-12-15	Sloan-Kettering Institute For Cancer Research	Coumarin-based compounds for the treatment of alzheimer's disease and cancer
CN102307892A (zh)	2008-12-31	2012-01-04	西尼克斯公司	环孢菌素a的衍生物
NZ593823A (en)	2009-01-06	2013-09-27	Curelon Llc	Compositions and methods for the treatment or the prevention of infections by e. coli
AU2010203709B2 (en)	2009-01-06	2014-05-22	Galenagen, Llc	Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces
WO2010088450A2 (en)	2009-01-30	2010-08-05	Celladon Corporation	Methods for treating diseases associated with the modulation of serca
US8389559B2 (en)	2009-02-09	2013-03-05	Sunovion Pharmaceuticals Inc.	Pyrrolidine triple reuptake inhibitors
EA201171035A1 (ru)	2009-02-10	2012-02-28	Селджин Корпорейшн	Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза
US8568793B2 (en)	2009-02-11	2013-10-29	Hope Medical Enterprises, Inc.	Sodium nitrite-containing pharmaceutical compositions
US20120053159A1 (en)	2009-02-11	2012-03-01	Muller George W	Isotopologues of lenalidomide
CN102388043A (zh)	2009-02-11	2012-03-21	桑诺维恩药品公司	组胺h3反相激动剂和拮抗剂及其使用方法
JP2012518635A (ja)	2009-02-24	2012-08-16	リターファーマシューティカルズインコーポレイテッド	プレバイオティック製剤および使用方法
WO2010099379A1 (en)	2009-02-27	2010-09-02	Ambit Biosciences Corporation	Jak kinase modulating quinazoline derivatives and methods of use thereof
WO2010101967A2 (en)	2009-03-04	2010-09-10	Idenix Pharmaceuticals, Inc.	Phosphothiophene and phosphothiazole hcv polymerase inhibitors
US20110229451A2 (en) *	2009-03-06	2011-09-22	Halozyme, Inc.	Temperature sensitive mutants of matrix metalloproteases and uses thereof
JP2012520314A (ja)	2009-03-11	2012-09-06	アムビトビオスシエンセスコルポラチオン	癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
EP2406266B1 (de) *	2009-03-11	2013-12-25	Kyorin Pharmaceutical Co., Ltd.	7-cycloalkylaminochinolone als gsk-3-hemmer
MX2011010105A (es)	2009-03-27	2012-01-12	Pathway Therapeutics Inc	Sulfonamidas de pirimidinilo y 1,3,5-triazinilo benzimidazol y su uso en terapia de cancer.
WO2010110686A1 (en)	2009-03-27	2010-09-30	Pathway Therapeutics Limited	Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US9056050B2 (en)	2009-04-13	2015-06-16	Curemark Llc	Enzyme delivery systems and methods of preparation and use
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
US8828953B2 (en) *	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
AU2010239311B2 (en)	2009-04-20	2014-05-22	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
MX357611B (es)	2009-04-22	2018-07-17	Axikin Pharmaceuticals Inc	Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
PE20120811A1 (es)	2009-04-22	2012-07-08	Axikin Pharmaceuticals Inc	Antagonistas ccr3 arilsulfonamida
EP2421829B1 (de)	2009-04-22	2015-09-30	Axikin Pharmaceuticals, Inc.	2,5-disubstituierte arylsulfonamide als ccr3-antagonisten
US9968574B2 (en) *	2009-05-15	2018-05-15	The University Of Kentucky Research Foundation	Treatment of MCI and Alzheimer's disease
EP2429992A4 (de) *	2009-05-15	2012-11-28	Univ Kentucky Res Found	Behandlung von leichter kognitiver beeinträchtigung und morbus alzheimer
GB2483815B (en)	2009-05-18	2013-12-25	Sigmoid Pharma Ltd	Composition comprising oil drops
WO2010137547A1 (ja)	2009-05-25	2010-12-02	国立大学法人東京工業大学	中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
AU2010258785A1 (en)	2009-06-10	2012-01-19	Sunovion Pharmaceuticals Inc.	Histamine H3 inverse agonists and antagonists and methods of use thereof
US9050276B2 (en)	2009-06-16	2015-06-09	The Trustees Of Columbia University In The City Of New York	Autism-associated biomarkers and uses thereof
WO2011003870A2 (en)	2009-07-06	2011-01-13	Creabilis S.A.	Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
AR080945A1 (es)	2009-07-07	2012-05-23	Pathway Therapeutics Inc	Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
HUE035519T2 (en)	2009-07-08	2018-05-02	Hope Medical Entpr Inc D B A Hope Pharmaceuticals	Sodium thiosulfate-containing pharmaceutical composition
EP2451274B1 (de)	2009-07-08	2017-10-04	Charleston Laboratories, Inc.	Pharmazeutische zusammensetzungen
WO2011006147A1 (en)	2009-07-10	2011-01-13	Scott Iii Linzy O	Methods and compositions for treating thyroid-related medical conditions with reduced folates
EP2467144A1 (de)	2009-07-24	2012-06-27	ViroLogik GmbH	Kombination aus proteasehemmern und antihepatitismedikation zur behandlung von hepatitis
US8404728B2 (en)	2009-07-30	2013-03-26	Mayo Foundation For Medical Education And Research	Small-molecule botulinum toxin inhibitors
WO2011014775A1 (en)	2009-07-31	2011-02-03	The Brigham And Women's Hospital, Inc.	Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
WO2011017389A1 (en)	2009-08-05	2011-02-10	Idenix Pharmaceuticals, Inc.	Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
EP2464341B1 (de)	2009-08-12	2022-07-06	Sublimity Therapeutics Limited	Immunmodulatorische zusammensetzungen mit einer polymermatrix und einer ölphase
BR112012003661A2 (pt)	2009-08-19	2017-04-25	Ambit Biosciences Corp	"compostos de biarila e métodos de uso dos mesmos."
US20120190743A1 (en)	2009-09-04	2012-07-26	United Paragon Associates Inc.	Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
US20120172350A1 (en)	2009-09-11	2012-07-05	Sunovion Pharmaceuticals Inc.	Histamine h3 inverse agonists and antagonists and methods of use thereof
US20110136751A1 (en)	2009-10-06	2011-06-09	Green Molecular	Use of Polyphenols in the Treatment of Cancer
US20120245186A1 (en)	2009-10-19	2012-09-27	Synta Pharmaceuticals Corp.	Combination cancer therapy with hsp90 inhibitory compounds
US8470817B2 (en) *	2009-10-26	2013-06-25	Sunesis Pharmaceuticals, Inc.	Compounds and methods for treatment of cancer
EP2325185A1 (de)	2009-10-28	2011-05-25	GPC Biotech AG	Plk-Inhibitor
WO2011056764A1 (en)	2009-11-05	2011-05-12	Ambit Biosciences Corp.	Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
US20110117055A1 (en)	2009-11-19	2011-05-19	Macdonald James E	Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
MX2012004741A (es)	2009-11-19	2012-05-22	Celgene Corp	Apremilast para el tratamiento de sarcoidosis.
WO2011064769A1 (en)	2009-11-24	2011-06-03	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en)	2009-12-02	2011-12-08	Alquest Therapeutics, Inc.	Organoselenium compounds and uses thereof
CA2782240A1 (en)	2009-12-04	2011-06-09	Sunovion Pharmaceuticals Inc.	Formulations, salts and polymorphs of transnorsertraline and uses thereof
RU2557059C2 (ru)	2009-12-04	2015-07-20	Суновион Фармасьютикалз, Инк.	Полициклические соединения и способы их применения
WO2011070364A1 (en)	2009-12-09	2011-06-16	Scynexis, Inc.	Novel cyclic peptides
AR079528A1 (es)	2009-12-18	2012-02-01	Idenix Pharmaceuticals Inc	Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
CN102770412A (zh)	2009-12-22	2012-11-07	细胞基因公司	(甲基磺酰基)乙基苯异吲哚啉衍生物及其治疗应用
US8710092B2 (en) *	2009-12-23	2014-04-29	Map Pharmaceuticals, Inc.	Substituted indolo 4,3 FG quinolines useful for treating migraine
CN102834409A (zh)	2009-12-30	2012-12-19	西尼克斯公司	环孢菌素类似物
ES2699692T3 (es)	2010-01-04	2019-02-12	Mapi Pharma Ltd	Sistema de depósito que comprende acetato de glatiramer
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US9226913B2 (en)	2010-01-05	2016-01-05	Celgene Corporation	Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereof
WO2011089167A1 (en)	2010-01-19	2011-07-28	Virologik Gmbh	Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011094890A1 (en)	2010-02-02	2011-08-11	Argusina Inc.	Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011097525A1 (en)	2010-02-05	2011-08-11	Tragara Pharmaceuticals, Inc.	Solid state forms of macrocyclic kinase inhibitors
SI2536706T1 (sl)	2010-02-11	2017-10-30	Celgene Corporation	Derivati arilmetoksi izoindolina in sestavki,ki jih vsebujejo ter metode uporabe le-teh
CA2825428C (en) *	2010-02-12	2022-06-14	Alexander Vuckovic, M.D., Llc	Compositions and methods for treating depression
AU2011223873B2 (en)	2010-03-02	2015-06-25	Axikin Pharmaceuticals, Inc.	Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en)	2010-03-11	2011-09-15	Ambit Biosciences Corp.	Saltz of an indazolylpyrrolotriazine
JP2013522236A (ja)	2010-03-12	2013-06-13	セルジーンコーポレイション	レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー
EP2547655B1 (de)	2010-03-17	2016-03-09	Axikin Pharmaceuticals, Inc.	Arylsulfonamid-ccr-3-antagonisten
WO2011116287A1 (en)	2010-03-19	2011-09-22	Purdue Research Foundation	Ccr5 modulators for treating hiv
MX341050B (es)	2010-04-07	2016-08-05	Celgene Corp *	Metodos para tratar infeccion viral respiratoria.
AU2011237592B2 (en)	2010-04-08	2016-10-27	Emory University	Substituted androst-4-ene diones
US20130156755A1 (en)	2010-04-19	2013-06-20	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP2560640A1 (de)	2010-04-19	2013-02-27	Synta Pharmaceuticals Corp.	Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer
EP3202406A1 (de)	2010-04-28	2017-08-09	Ritter Pharmaceuticals, Inc.	Präbiotische formulierungen und deren verwendungen
WO2011140360A1 (en)	2010-05-05	2011-11-10	The Trustees Of Columbia University In The City Of New York	Radiolabeled compounds and uses thereof
WO2011146803A1 (en)	2010-05-20	2011-11-24	Synta Pharmaceuticals Corp.	Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
US20130171105A1 (en)	2010-05-24	2013-07-04	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2011150156A2 (en)	2010-05-26	2011-12-01	Sunovion Pharmaceuticals Inc.	Heteroaryl compounds and methods of use thereof
WO2011150201A2 (en)	2010-05-27	2011-12-01	Ambit Biosciences Corporation	Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en)	2010-05-27	2011-12-01	Ambit Biosciences Corporation	Azolyl urea compounds and methods of use thereof
EP2576520A1 (de)	2010-05-28	2013-04-10	GE Healthcare UK Limited	Radioaktiv markierte verbindungen und ihre verfahren
CA2801001A1 (en)	2010-06-01	2011-12-08	Biotheryx, Inc.	Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
EP2585063A1 (de)	2010-06-01	2013-05-01	Biotheryx Inc.	Verfahren zur behandlung von hämatologischen malignomen mit 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridon
MX2012014273A (es)	2010-06-07	2013-03-22	Novomedix Llc	Compuestos furanilo y su uso.
US20130178522A1 (en)	2010-07-19	2013-07-11	James M. Jamison	Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
ES2591355T3 (es)	2010-08-24	2016-11-28	Algiax Pharmaceuticals Gmbh	Uso novedoso de leflunomida y malononitrilamidas
WO2012030913A1 (en)	2010-09-01	2012-03-08	Ambit Biosciences Corporation	An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
US20130225578A1 (en)	2010-09-01	2013-08-29	Ambit Biosciences Corporation	7-cyclylquinazoline derivatives and methods of use thereof
EP2611502A1 (de)	2010-09-01	2013-07-10	Ambit Biosciences Corporation	Adenosin-a3-rezeptormodulierende verbindungen und ihre verwendung
US20130296363A1 (en)	2010-09-01	2013-11-07	Ambit Biosciences Corporation	Quinoline and isoquinoline derivatives for use as jak modulators
WO2012030924A1 (en)	2010-09-01	2012-03-08	Ambit Biosciences Corporation	Azolopyridine and azolopyrimidine compounds and methods of use thereof
KR20130102060A (ko)	2010-09-01	2013-09-16	암비트 바이오사이언시즈 코포레이션	퀴나졸린 화합물 및 이의 사용 방법
EP2611792B1 (de)	2010-09-01	2017-02-01	Ambit Biosciences Corporation	Hydrobromid salze einer pyrazolylaminoquinazolin
WO2012030910A1 (en)	2010-09-01	2012-03-08	Ambit Biosciences Corporation	2-cycloquinazoline derivatives and methods of use thereof
EP2611794A1 (de)	2010-09-01	2013-07-10	Ambit Biosciences Corporation	4--azolylaminochinazolinderivate und verwendungsverfahren dafür
WO2012030894A1 (en)	2010-09-01	2012-03-08	Ambit Biosciences Corporation	Thienopyridine and thienopyrimidine compounds and methods of use thereof
JP2013537229A (ja)	2010-09-13	2013-09-30	シンタファーマシューティカルズコーポレーション	野生型ｅｇｆｒ及び／又はｋｒａｓ患者において非小細胞肺癌を処置するためのｈｓｐ９０阻害剤
WO2012044641A1 (en)	2010-09-29	2012-04-05	Pathway Therapeutics Inc.	1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MX2013003954A (es)	2010-10-11	2013-08-01	Axikin Pharmaceuticals Inc	Sales de arilsulfonamida antagonistas de ccr3.
EP2627349B1 (de)	2010-10-15	2016-02-03	The Trustees of Columbia University in the City of New York	Gene und zugehörige proteine im zusammenhang mit adipositas sowie verwendungen davon
MX337179B (es)	2010-10-18	2016-02-15	Cerenis Therapeutics Holding Sa	Compuestos, composiciones y metodos utiles para la movilizacion de colesterol.
CA2815024A1 (en)	2010-10-19	2012-04-26	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
CA2814371C (en)	2010-10-29	2019-03-19	Algiax Pharmaceuticals Gmbh	Use of malononitrilamides in neuropathic pain
WO2012064808A1 (en)	2010-11-09	2012-05-18	Synta Pharmaceuticals Corp	Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
EP2637669A4 (de)	2010-11-10	2014-04-02	Infinity Pharmaceuticals Inc	Heterocyclische verbindungen und ihre verwendung
GB201020032D0 (en)	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
AU2011338530B2 (en)	2010-12-06	2017-06-15	Follica, Inc.	Methods for treating baldness and promoting hair growth
WO2012078492A1 (en)	2010-12-06	2012-06-14	Celgene Corporation	A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
EP2648708A2 (de)	2010-12-08	2013-10-16	Synta Pharmaceuticals Corp.	Kombinationskrebstherapie für brustkrebs mit hsp90-hemmerverbindungen
WO2012080050A1 (en)	2010-12-14	2012-06-21	F. Hoffmann-La Roche Ag	Solid forms of a phenoxybenzenesulfonyl compound
US9532977B2 (en)	2010-12-16	2017-01-03	Celgene Corporation	Controlled release oral dosage forms of poorly soluble drugs and uses thereof
EP2651400B2 (de)	2010-12-16	2023-01-18	Amgen (Europe) GmbH	Orale retard-darreichungsformen von schwer löslichen arzneimitteln und ihre verwendung
EP2654751B1 (de)	2010-12-22	2016-11-23	Purdue Pharma L.P.	Phosphorsubstituierte quinoxalin-piperidinverbindungen und verwendungen davon
WO2013103919A2 (en)	2012-01-06	2013-07-11	Elcelyx Therapeutics, Inc.	Compositions and methods for treating metabolic disorders
PT2661266T (pt)	2011-01-07	2020-11-30	Anji Pharma Us Llc	Terapias com base em ligandos do recetor quimiossensorial
CN103391770A (zh)	2011-01-10	2013-11-13	细胞基因公司	环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型
WO2012096884A1 (en)	2011-01-10	2012-07-19	Celgene Corporation	Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
CA2824197C (en)	2011-01-10	2020-02-25	Michael Martin	Processes for preparing isoquinolinones and solid forms of isoquinolinones
EP2663305A1 (de)	2011-01-11	2013-11-20	Synta Pharmaceuticals Corp.	Kombinationstherapie aus hsp90-hemmenden verbindungen und proteasom-hemmern
AU2012205687B2 (en)	2011-01-11	2017-03-16	Sunovion Pharmaceuticals Inc.	Heteroaryl compounds and methods of use thereof
US9045417B2 (en)	2011-01-14	2015-06-02	Celgene Corporation	Isotopologues of isoindole derivatives
EP3042654A1 (de)	2011-01-20	2016-07-13	Bionevia Pharmaceuticals Inc.	Zusammensetzungen mit veränderter freisetzung von epalrestat oder einem derivat davon und verwendungsverfahren dafür
WO2012106281A2 (en)	2011-01-31	2012-08-09	The General Hospital Corporation	Multimodal trail molecules and uses in cellular therapies
JP2014503597A (ja)	2011-01-31	2014-02-13	セルジーンコーポレイション	シチジンアナログの医薬組成物及びその使用方法
US9353100B2 (en)	2011-02-10	2016-05-31	Idenix Pharmaceuticals Llc	Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012116061A1 (en)	2011-02-23	2012-08-30	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitory compounds with radiotherapy
WO2012141796A2 (en)	2011-02-24	2012-10-18	Synta Pharmaceuticals Corp.	Prostate cancer therapy with hsp90 inhibitory compounds
US20140045908A1 (en)	2011-02-25	2014-02-13	Synta Pharmaceuticals Corp.	Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US9795792B2 (en)	2011-02-25	2017-10-24	Medtronic, Inc.	Emergency mode switching for non-pacing modes
WO2012121988A2 (en)	2011-03-07	2012-09-13	Celgene Corporation	Methods for treating diseases using isoindoline compounds
MX2013010217A (es)	2011-03-11	2013-10-25	Celgene Corp	Uso de 3 - (5 - amino - 2 - metil - 4 - oxoquinazolin - 3 (4h) - il) piperidin - 2, 6 - diona en tratamiento de enfermedades inmunorrelacionadas e inflamatorias.
KR20140014221A (ko)	2011-03-11	2014-02-05	셀진 코포레이션	3-(5-아미노-2-메틸-4-옥소-4ｈ-퀴나졸린-3-일)-피페리딘-2,6-디온의 고체 형태, 및 그의 제약 조성물 및 용도
WO2012123353A1 (en)	2011-03-17	2012-09-20	Algiax Pharmaceuticals Gmbh	Novel use of benzofuranylsulfonates
EP2685983B1 (de)	2011-03-17	2016-05-18	Algiax Pharmaceuticals GmbH	Neue verwendung von imidazotriazinonen
WO2012129237A2 (en)	2011-03-20	2012-09-27	Trustees Of Boston University	Therapeutic agent for emphysema and copd
BR112013024907A2 (pt)	2011-03-28	2016-12-20	Mei Pharma Inc	composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k
CA2831590A1 (en)	2011-03-28	2012-10-04	Mei Pharma, Inc.	(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135166A1 (en)	2011-03-28	2012-10-04	Pathway Therapeutics Inc.	(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
CA2867134C (en)	2011-03-28	2019-05-07	Sheila Dewitt	2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2843324A1 (en)	2011-03-31	2012-11-15	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en)	2011-03-31	2012-10-04	Idenix Pharmaceuticals, Inc.	Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US20120321590A1 (en)	2011-04-06	2012-12-20	Anadys Pharmaceuticals, Inc.	Bridged polycyclic compounds
DK2701733T3 (da)	2011-04-21	2019-05-27	Curemark Llc	Forbindelser til behandling af neuropsykiatriske forstyrrelser
WO2012143924A1 (en)	2011-04-21	2012-10-26	Mapi Pharma Ltd.	Random pentapolymer for treatment of autoimmune diseases
WO2012149251A1 (en)	2011-04-28	2012-11-01	Celgene Corporation	Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
KR20140024914A (ko)	2011-04-29	2014-03-03	셀진 코포레이션	예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
EP2704701B1 (de)	2011-05-03	2018-01-03	PRCL Research Inc.	Verbindungen zur verwendung gegen entzündungs- und immunspezifische erkrankungen
EP2704726B1 (de)	2011-05-04	2018-10-31	Trustees of Boston University	Protonenantriebskraftstimulation zur potenzierung von aminoglycosid-antibiotika gegen persistente bakterien
WO2012162372A1 (en)	2011-05-24	2012-11-29	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
CN103747787A (zh)	2011-05-27	2014-04-23	坦普尔大学	取代的2-亚苄基-2H-苯并[b][1,4]噻嗪-3(4H)-酮类、其衍生物及其治疗应用
WO2012170536A1 (en)	2011-06-07	2012-12-13	Anadys Pharmaceuticals, Inc.	[1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
RU2011122942A (ru)	2011-06-08	2012-12-20	Общество С Ограниченной Ответственностью "Асинэкс Медхим"	Новые ингибиторы киназ
CN105693712A (zh)	2011-06-22	2016-06-22	普渡制药公司	包含二羟基取代基的trpv1拮抗剂及其用途
WO2012177678A2 (en)	2011-06-22	2012-12-27	Celgene Corporation	Isotopologues of pomalidomide
CN103827113A (zh)	2011-06-23	2014-05-28	Map药物公司	新型氟麦角碱类似物
US20140227293A1 (en)	2011-06-30	2014-08-14	Trustees Of Boston University	Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
JP2014520808A (ja)	2011-07-07	2014-08-25	シンタファーマシューティカルズコーポレーション	Ｈｓｐ９０阻害化合物を用いた癌の治療
US8969363B2 (en)	2011-07-19	2015-03-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA2842190A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
GB201112987D0 (en)	2011-07-28	2011-09-14	Ge Healthcare Ltd	Novel compound
WO2013021276A1 (en)	2011-08-10	2013-02-14	Purdue Pharma L.P.	Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013022872A1 (en)	2011-08-10	2013-02-14	Celgene Corporation	Gene methylation biomarkers and methods of use thereof
CN103930126A (zh)	2011-08-12	2014-07-16	Bsrc亚历山大.弗莱明	Tnf超家族三聚化的抑制剂
EP2744494A1 (de)	2011-08-19	2014-06-25	Synta Pharmaceuticals Corporation	Kombinationskrebstherapie mit einem hsp90-inhibitor mit antimetaboliten
DK2959899T3 (en)	2011-08-23	2017-05-01	Cornerstone Therapeutics Inc	Use of zileuton for the treatment of nasal polyps in patients with cystic fibrosis
RU2014111823A (ru)	2011-08-29	2015-10-10	Инфинити Фармасьютикалз, Инк.	Гетероциклические соединения и их применения
EP2755985B1 (de)	2011-09-12	2017-11-01	Idenix Pharmaceuticals LLC	Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
AR088441A1 (es)	2011-09-12	2014-06-11	Idenix Pharmaceuticals Inc	Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013040501A1 (en)	2011-09-16	2013-03-21	Pharmathene, Inc.	Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
AU2012312308B2 (en)	2011-09-23	2015-11-19	Celgene Corporation	Romidepsin and 5-azacitidine for use in treating lymphoma
WO2013049093A1 (en)	2011-09-26	2013-04-04	Celgene Corporation	Combination therapy for chemoresistant cancers
US9630979B2 (en)	2011-09-29	2017-04-25	Infinity Pharmaceuticals, Inc.	Inhibitors of monoacylglycerol lipase and methods of their use
EP2764406B1 (de)	2011-10-07	2018-03-14	Cedars-Sinai Medical Center	Zusammensetzungen und verfahren für tumorbildgebung und -anzielung mit einer klasse organischer heptamethincyaninfarbstoffe mit nuklear- und nahinfrarot-eigenschaften
WO2013055985A1 (en)	2011-10-12	2013-04-18	Children's Medical Center Corporation	Combinatorial compositions and methods of treating hemoglobinopathies
WO2013056070A2 (en)	2011-10-14	2013-04-18	Ambit Biosciences Corporation	Heterocyclic compounds and methods of use thereof
AR089650A1 (es)	2011-10-14	2014-09-10	Idenix Pharmaceuticals Inc	Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
KR20140088603A (ko)	2011-11-01	2014-07-10	셀진 코포레이션	시티딘 유사체의 경구 제제를 사용하여 암을 치료하는 방법
JP2014532712A (ja)	2011-11-02	2014-12-08	シンタファーマシューティカルズコーポレーション	トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
US20140286902A1 (en)	2011-11-02	2014-09-25	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013066375A1 (en) *	2011-11-05	2013-05-10	South Alabama Medical Science Foundation	Methods, formulations, and kits for rapidly repleting folate levels in women
US9243037B2 (en)	2011-11-10	2016-01-26	Trustees Of Boston College	Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
JP2014533299A (ja)	2011-11-14	2014-12-11	シンタファーマシューティカルズコーポレーション	Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法
US9290488B2 (en)	2011-12-01	2016-03-22	Purdue Pharma L.P.	Azetidine-substituted quinoxalines as opioid receptor like-1 modulators
US20130143867A1 (en)	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013085902A1 (en)	2011-12-05	2013-06-13	The University Of Texas M.D.	Combination therapy methods for treating an inflammatory breast cancer
WO2013084060A1 (en)	2011-12-08	2013-06-13	Purdue Pharma L.P.	Quaternized buprenorphine analogs
SG10201509139QA (en)	2011-12-19	2015-12-30	Map Pharmaceuticals Inc	Novel iso-ergoline derivatives
US8946420B2 (en)	2011-12-21	2015-02-03	Map Pharmaceuticals, Inc.	Neuromodulatory compounds
PT3130347T (pt)	2011-12-30	2019-12-10	Halozyme Inc	Variantes de polipéptidos de ph20, suas formulações e utilizações
RU2674153C2 (ru)	2012-01-05	2018-12-05	Бостон Медикал Сентер Корпорэйшн	Slit-robo сигналинг для диагностики и лечения заболевания почек
ES2832773T3 (es)	2012-01-06	2021-06-11	Anji Pharma Us Llc	Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos
AU2013216935C1 (en)	2012-02-08	2017-12-14	John Emmerson Campbell	Heteroaryl compounds and methods of use thereof
WO2013126394A1 (en)	2012-02-21	2013-08-29	Celgene Corporation	Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
US20150018362A1 (en)	2012-02-27	2015-01-15	Biovista, Inc.	Compositions and methods for treating mitochondrial diseases
WO2013130600A1 (en)	2012-02-29	2013-09-06	Ambit Biosciences Corporation	Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013133708A1 (en)	2012-03-07	2013-09-12	Stichting Vu-Vumc	Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
US8916555B2 (en)	2012-03-16	2014-12-23	Axikin Pharmaceuticals, Inc.	3,5-diaminopyrazole kinase inhibitors
ES2779698T3 (es)	2012-03-19	2020-08-18	Brigham & Womens Hospital Inc	Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad
WO2013139861A1 (en)	2012-03-20	2013-09-26	Luc Montagnier	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US20140350087A9 (en)	2012-03-22	2014-11-27	Halozyme, Inc.	Oncovector Nucleic Acid Molecules and Methods of Use
WO2013148864A1 (en)	2012-03-27	2013-10-03	Andrei Gudkov	Curaxins for use in treating breast cancer and method for identifying patients likely to respond
US20150051203A1 (en)	2012-03-28	2015-02-19	Synta Pharmaceuticals Corp.	Triazole derivatives as hsp90 inhibitors
CA2868323A1 (en)	2012-04-04	2013-10-10	Synta Pharmaceuticals Corp.	Novel triazole compounds that modulate hsp90 activity
CA2986512C (en)	2012-04-04	2022-05-17	Halozyme, Inc.	Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013156232A1 (en)	2012-04-16	2013-10-24	Algiax Pharmaceuticals Gmbh	Use of benzofuranylsulfonates in neuropathic pain
WO2013156231A1 (en)	2012-04-16	2013-10-24	Algiax Pharmaceuticals Gmbh	Use of imidazotriazinones in neuropathic pain
TW201811332A (zh)	2012-04-17	2018-04-01	美商普渡製藥有限合夥事業	處理由類鴉片引起之不利的藥效動力反應之系統和方法
WO2013158928A2 (en)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
CA3095012C (en)	2012-05-01	2023-02-07	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
EP2849751A1 (de)	2012-05-10	2015-03-25	Synta Pharmaceuticals Corp.	Behandlung von krebs mit hsp90-hemmenden verbindungen
CA2870605A1 (en)	2012-05-11	2013-11-14	Purdue Pharma L.P.	Benzomorphan compounds as opioid receptors modulators
US9296778B2 (en)	2012-05-22	2016-03-29	Idenix Pharmaceuticals, Inc.	3′,5′-cyclic phosphate prodrugs for HCV infection
PE20150132A1 (es)	2012-05-22	2015-02-14	Idenix Pharmaceuticals Inc	Compuestos d-aminoacidos para enfermedad hepatica
WO2013177188A1 (en)	2012-05-22	2013-11-28	Idenix Pharmaceuticals, Inc.	3',5'-cyclic phosphoramidate prodrugs for hcv infection
US10350278B2 (en)	2012-05-30	2019-07-16	Curemark, Llc	Methods of treating Celiac disease
EP3406598B1 (de)	2012-06-14	2020-01-29	Mayo Foundation for Medical Education and Research	Pyrazolderivate als hemmer von stat3
US9789193B2 (en)	2012-06-15	2017-10-17	The Brigham And Women's Hospital, Inc.	Compositions for treating cancer and methods for making the same
US9012640B2 (en)	2012-06-22	2015-04-21	Map Pharmaceuticals, Inc.	Cabergoline derivatives
JP6318152B2 (ja)	2012-06-29	2018-04-25	セルジーンコーポレイション	セレブロン関連タンパク質を利用して薬物効能を決定する方法
GB201212010D0 (en)	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
JP2015522080A (ja)	2012-07-11	2015-08-03	エルセリクスセラピューティクスインコーポレイテッド	スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
US9034870B2 (en)	2012-07-13	2015-05-19	Purdue Research Foundation	Azaindenoisoquinoline topoisomerase I inhibitors
US9085561B2 (en)	2012-07-30	2015-07-21	Purdue Pharma L.P.	Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014022332A1 (en)	2012-07-31	2014-02-06	The Brigham And Women's Hospital, Inc.	Modulation of the immune response
UA114521C2 (uk)	2012-08-09	2017-06-26	Селджин Корпорейшн	Солі і тверді форми (s)-3-(4-((4-морфолінометил)-бензил)оксі)-1-оксоізоіндолін-2-іл)-піперидин-2,6-діону і композиції, які їх включають, і способи їхнього застосування
PL2882441T3 (pl)	2012-08-09	2020-09-21	Celgene Corporation	Leczenie chorób immunologicznych i zapalnych
TWI653977B (zh)	2012-08-09	2019-03-21	美商西建公司	利用３－（４－（（４－（嗎啉基甲基）苄基）氧基）－１－氧異吲哚啉－２－基）六氫吡啶－２，６－二酮治療癌症之方法
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014030053A1 (en)	2012-08-20	2014-02-27	Rhodes Technologies	Systems and methods for increasing stability of dronabinol compositions
US9315514B2 (en)	2012-08-27	2016-04-19	Rhodes Technologies	1,3-dioxanomorphides and 1,3-dioxanocodides
US9605074B2 (en)	2012-08-30	2017-03-28	The General Hospital Corporation	Multifunctional nanobodies for treating cancer
CA2922849A1 (en)	2012-08-31	2014-03-06	Ixchel Pharma, Llc	Agents useful for treating obesity, diabetes and related disorders
TW201414721A (zh)	2012-09-07	2014-04-16	Axikin Pharmaceuticals Inc	同位素濃化之芳磺醯胺ｃｃｒ３拮抗劑
JP6306592B2 (ja)	2012-09-10	2018-04-04	セルジーンコーポレイション	局所進行乳癌を治療するための方法
WO2014055647A1 (en)	2012-10-03	2014-04-10	Mei Pharma, Inc.	(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
AP2015008384A0 (en)	2012-10-08	2015-04-30	Univ Montpellier Ct Nat De La Rech Scient	2'-Chloro nucleoside analogs for hcv infection
KR102229873B1 (ko)	2012-10-12	2021-03-19	더 브리검 앤드 우먼즈 하스피털, 인크.	면역 반응의 향상
US9278124B2 (en)	2012-10-16	2016-03-08	Halozyme, Inc.	Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20140112886A1 (en)	2012-10-19	2014-04-24	Idenix Pharmaceuticals, Inc.	Dinucleotide compounds for hcv infection
WO2014066239A1 (en)	2012-10-22	2014-05-01	Idenix Pharmaceuticals, Inc.	2',4'-bridged nucleosides for hcv infection
PT2914296T (pt)	2012-11-01	2018-10-30	Infinity Pharmaceuticals Inc	Tratamento de cancros utilizando moduladores de isoformas de pi3-quinase
CA2890177A1 (en)	2012-11-08	2014-05-15	Summa Health System	Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
EP2917182B1 (de)	2012-11-09	2018-01-03	Purdue Pharma LP	Benzomorphan-analoge und ihre verwendung
US20150290171A1 (en)	2012-11-09	2015-10-15	Celgene Corporation	Methods for the treatment of bone loss
US20140140951A1 (en)	2012-11-14	2014-05-22	Idenix Pharmaceuticals, Inc.	D-Alanine Ester of Rp-Nucleoside Analog
US20140140952A1 (en)	2012-11-14	2014-05-22	Idenix Pharmaceuticals, Inc.	D-Alanine Ester of Sp-Nucleoside Analog
EP2925762B1 (de)	2012-11-29	2017-07-05	Sunovion Pharmaceuticals Inc.	Triazolo-pyrazin-derivate zur behandlung von erkrankungen des zentralen nervensystems
WO2014085633A1 (en)	2012-11-30	2014-06-05	Novomedix, Llc	Substituted biaryl sulfonamides and the use thereof
WO2014087226A1 (en)	2012-12-07	2014-06-12	Purdue Pharma L.P.	Buprenorphine analogs as opiod receptor modulators
ES2621305T3 (es)	2012-12-14	2017-07-03	Purdue Pharma Lp	Morfinanos espirocíclicos y su uso
WO2014091295A1 (en)	2012-12-14	2014-06-19	Purdue Pharma L.P.	Pyridonemorphinan analogs and biological activity on opioid receptors
TW201434836A (zh)	2012-12-14	2014-09-16	Purdue Pharma Lp	包含氮之嗎啡喃衍生物及其用途
US9211300B2 (en)	2012-12-19	2015-12-15	Idenix Pharmaceuticals Llc	4′-fluoro nucleosides for the treatment of HCV
EP2934143A4 (de)	2012-12-21	2016-06-15	Map Pharmaceuticals Inc	Neuartige methysergidderivate
WO2014102590A1 (en)	2012-12-27	2014-07-03	Purdue Pharma L.P.	Substituted piperidin-4-amino-type compounds and uses thereof
US9963458B2 (en)	2012-12-27	2018-05-08	Purdue Pharma L.P.	Indole and indoline-type piperidine compounds and uses thereof
WO2014102594A2 (en)	2012-12-27	2014-07-03	Purdue Pharma L.P.	Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102589A1 (en)	2012-12-27	2014-07-03	Purdue Pharma L.P.	Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
WO2014102592A2 (en)	2012-12-27	2014-07-03	Purdue Pharma L.P.	Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
EP2941430B1 (de)	2012-12-28	2017-04-26	Purdue Pharma LP	7,8-cyclicmorphinan-analoge
WO2014102593A1 (en)	2012-12-28	2014-07-03	Purdue Pharma L.P.	Substituted morphinans and the use thereof
US9884844B2 (en)	2012-12-31	2018-02-06	Sunovion Pharmaceuticals, Inc.	Heterocyclic compounds and methods of use thereof
SG10201705437SA (en)	2013-01-05	2017-07-28	Elcelyx Therapeutics Inc	Delayed-release composition comprising biguanide
WO2014107745A1 (en)	2013-01-07	2014-07-10	Halozyme, Inc.	Metal sensitive mutants of matrix metalloproteases and uses thereof
US9617607B2 (en)	2013-01-08	2017-04-11	Enzo Biochem, Inc.	Diagnosis and treatment of viral diseases
WO2014110127A1 (en)	2013-01-08	2014-07-17	Enzo Biochem, Inc.	Diagnosis and treatment of viral diseases
WO2014110305A1 (en)	2013-01-11	2014-07-17	Mayo Foundation For Medical Education And Research	Vitamins c and k for treating polycystic diseases
AU2014205043B2 (en)	2013-01-14	2018-10-04	Deuterx, Llc	3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9695145B2 (en)	2013-01-22	2017-07-04	Celgene Corporation	Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
CN104955483A (zh)	2013-01-30	2015-09-30	法莫斯医疗公司	用低剂量药剂治疗抑郁症和其它疾病
EP2951160B1 (de)	2013-01-31	2019-04-24	Purdue Pharma LP	Benzomorphan-analoga und verwendung davon
WO2014130922A1 (en)	2013-02-25	2014-08-28	Trustees Of Boston University	Compositions and methods for treating fungal infections
US9309275B2 (en)	2013-03-04	2016-04-12	Idenix Pharmaceuticals Llc	3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en)	2013-03-04	2014-09-12	Idenix Pharmaceuticals, Inc.	Thiophosphate nucleosides for the treatment of hcv
CN105050624A (zh)	2013-03-14	2015-11-11	细胞基因公司	利用阿普斯特来治疗银屑病关节炎的方法
US8969358B2 (en)	2013-03-15	2015-03-03	Purdue Pharma L.P.	Buprenorphine analogs
NZ629037A (en)	2013-03-15	2017-04-28	Infinity Pharmaceuticals Inc	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN107056838A (zh)	2013-03-15	2017-08-18	加利福尼亚大学董事会	无环核苷膦酸二酯
WO2014165542A1 (en)	2013-04-01	2014-10-09	Idenix Pharmaceuticals, Inc.	2',4'-fluoro nucleosides for the treatment of hcv
CN105246480A (zh)	2013-04-02	2016-01-13	细胞基因公司	使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物
EP4140497A1 (de)	2013-04-08	2023-03-01	President and Fellows of Harvard College	Zusammensetzungen zum verjüngen von stammzellen der skelettmuskulatur
KR20160013204A (ko)	2013-05-30	2016-02-03	인피니티 파마슈티칼스, 인코포레이티드	Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
CN105431144A (zh)	2013-06-05	2016-03-23	思康脑侒股份有限公司	阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
EP3004130B1 (de)	2013-06-05	2019-08-07	Idenix Pharmaceuticals LLC.	1',4'-thionukleoside zur behandlung von hcv
US20160113911A1 (en)	2013-06-06	2016-04-28	The General Hospital Corporation	Methods and compositions for the treatment of cancer
WO2014201143A1 (en)	2013-06-11	2014-12-18	President And Fellows Of Harvard College	Methods and compositions for increasing neurogenesis and angiogenesis
BR112015031278B1 (pt)	2013-06-14	2022-05-17	Akamara Therapeutics, Inc	Compostos e nanopartículas de platina com base em lipídio, seus processos de preparação, composições farmacêuticas compreendendo os mesmos e seus usos no tratamento de câncer
EP2815749A1 (de)	2013-06-20	2014-12-24	IP Gesellschaft für Management mbH	Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
US20160120861A1 (en)	2013-06-28	2016-05-05	Purdue Pharma L.P.	Compositions and Methods for Treating an Arrhythmia with an Opioid Antagonist
TW201534726A (zh)	2013-07-03	2015-09-16	Halozyme Inc	熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015017713A1 (en)	2013-08-01	2015-02-05	Idenix Pharmaceuticals, Inc.	D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015027146A1 (en)	2013-08-22	2015-02-26	The General Hospital Corporation	Inhibitors of human 12/15-lipoxygenase
US11382883B2 (en)	2013-08-29	2022-07-12	Trustees Of Boston University	Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
KR20160055170A (ko)	2013-08-30	2016-05-17	암비트 바이오사이언시즈 코포레이션	바이아릴 아세트아미드 화합물 및 이의 사용 방법
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (de)	2013-09-20	2016-07-27	IDENIX Pharmaceuticals, Inc.	Inhibitoren des hepatitis-c-virus
ES2729642T3 (es)	2013-09-24	2019-11-05	Purdue Pharma Lp	Tratamiento del dolor por quemaduras mediante moduladores de TRPV1
US9700549B2 (en)	2013-10-03	2017-07-11	David Wise	Compositions and methods for treating pelvic pain and other conditions
BR112016007467B1 (pt)	2013-10-04	2022-09-20	Infinity Pharmaceuticals, Inc	Compostos heterocíclicos e usos dos mesmos
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US20160244452A1 (en)	2013-10-21	2016-08-25	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP2016536303A (ja)	2013-10-21	2016-11-24	ザジェネラルホスピタルコーポレイション	末梢循環腫瘍細胞クラスターおよび癌処置に関する方法
WO2015061683A1 (en)	2013-10-25	2015-04-30	Idenix Pharmaceuticals, Inc.	D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065876A1 (en)	2013-10-29	2015-05-07	Thomas Jefferson University	Methods of prevention or treatment for pathologic thrombosis or inflammation
US20160271162A1 (en)	2013-11-01	2016-09-22	Idenix Pharmacueticals, Llc	D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
GB201319792D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
ES2860773T3 (es)	2013-11-11	2021-10-05	Naturex Inc	Composiciones y métodos útiles en el tratamiento de síntomas del tracto urinario inferior, hiperplasia prostática benigna, disfunción eréctil
EP4053560A1 (de)	2013-11-26	2022-09-07	The Brigham and Women's Hospital, Inc.	Zusammensetzungen und verfahren zur modulierung einer immunreaktion
WO2015081133A2 (en)	2013-11-27	2015-06-04	Idenix Pharmaceuticals, Inc.	Nucleotides for the treatment of liver cancer
EP3074399A1 (de)	2013-11-27	2016-10-05	Idenix Pharmaceuticals LLC	2'-dichlor- und 2'-fluor-2'-chlor-nukleosidanaloga für hcv-infektion
CA2933335A1 (en)	2013-12-11	2015-06-18	The General Hospital Corporation	Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
EP3083654A1 (de)	2013-12-18	2016-10-26	Idenix Pharmaceuticals LLC	4'-or-nukleoside zur behandlung von hcv
US9682123B2 (en)	2013-12-20	2017-06-20	The Trustees Of Columbia University In The City Of New York	Methods of treating metabolic disease
CA2934344A1 (en)	2013-12-20	2015-06-25	David T. TING	Methods and assays relating to circulating tumor cells
EP3087079B1 (de)	2013-12-26	2019-04-03	Purdue Pharma LP	Opioidrezeptormodulierende oxabicyclo[2.2.2]oktanmorphinane
US9994571B2 (en)	2013-12-26	2018-06-12	Purdue Pharma L.P.	10-substituted morphinan hydantoins
WO2015097546A1 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	Propellane-based compounds and their use as opioid receptor modulators
WO2015097548A1 (en)	2013-12-26	2015-07-02	Purdue Pharma L.P.	7-beta-alkyl analogs of orvinols
WO2015099863A1 (en)	2013-12-27	2015-07-02	Purdue Pharma L.P.	6-substituted and 7-substituted morphinan analogs and the use thereof
EP3089978B1 (de)	2013-12-30	2018-08-29	Purdue Pharma L.P.	Pyridonsulfonmorphinan-analoga als opioidrezeptorliganden
EP3094328B1 (de)	2014-01-15	2020-08-19	Poxel SA	Verfahren zur behandlung von neurologischen, stoffwechsel- und anderen erkrankungen mit enantiomerenreinem deuterium-angereicherten pioglitazon
EP3096749B1 (de)	2014-01-24	2019-05-15	Celgene Corporation	Verfahren zur behandlung von adipositas mit apremilast
US20170066779A1 (en)	2014-03-05	2017-03-09	Idenix Pharmaceuticals Llc	Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CA2942313C (en)	2014-03-10	2023-02-07	Kadmon Corporation, Llc	Treatment of brain and central nervous system tumors
AU2015233686B2 (en)	2014-03-18	2019-07-11	Algiax Pharmaceuticals Gmbh	2-Cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives
CN113620958A (zh)	2014-03-19	2021-11-09	无限药品股份有限公司	用于治疗PI3K-γ介导的障碍的杂环化合物
US10005765B2 (en)	2014-03-20	2018-06-26	Capella Therapeutics, Inc.	Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US11369588B2 (en)	2014-03-20	2022-06-28	The Trustees Of Princeton University	NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
CA2943231C (en)	2014-03-20	2023-10-24	Capella Therapeutics, Inc.	Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2015143343A2 (en)	2014-03-21	2015-09-24	The Brigham And Women's Hospital, Inc.	Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
CA2944401A1 (en)	2014-04-03	2015-10-08	Invictus Oncology Pvt. Ltd.	Supramolecular combinatorial therapeutics
EP3125905A4 (de)	2014-04-04	2017-11-08	Ritter Pharmaceuticals, Inc.	Verfahren und zusammensetzungen für mikrobiomveränderung
CA2944549A1 (en)	2014-04-09	2015-10-15	Siteone Therapeutics, Inc.	10',11'-modified saxitoxin useful for the treatment of pain
WO2015161137A1 (en)	2014-04-16	2015-10-22	Idenix Pharmaceuticals, Inc.	3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
EP3804745A1 (de)	2014-04-25	2021-04-14	The Brigham and Women's Hospital, Inc.	Verfahren zur manipulation von alpha-fetoprotein (afp)
ES2830849T3 (es)	2014-04-25	2021-06-04	Brigham & Womens Hospital Inc	Ensayo y método para tratar sujetos con enfermedades inmunomediadas
WO2015168079A1 (en)	2014-04-29	2015-11-05	Infinity Pharmaceuticals, Inc.	Pyrimidine or pyridine derivatives useful as pi3k inhibitors
SG11201609256SA (en)	2014-05-12	2016-12-29	Conatus Pharmaceuticals Inc	Treatment of the complications of chronic liver disease with caspase inhibitors
WO2015175773A1 (en)	2014-05-15	2015-11-19	Celgene Corporation	Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
WO2015175956A1 (en)	2014-05-16	2015-11-19	Celgene Corporation	Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
EP3145906B1 (de)	2014-05-19	2023-10-04	Northeastern University	Auf serotoninrezeptor abzielende verbindungen
WO2015176780A1 (en)	2014-05-23	2015-11-26	Sigmoid Pharma Limited	Celecoxib formulations useful for treating colorectal cancer
AU2015265607A1 (en)	2014-05-28	2016-11-17	Idenix Pharmaceuticals Llc	Nucleoside derivatives for the treatment of cancer
US10456445B2 (en)	2014-06-02	2019-10-29	Children's Medical Center Corporation	Methods and compositions for immunomodulation
WO2015191900A1 (en)	2014-06-12	2015-12-17	Ligand Pharmaceuticals, Inc.	Glucagon antagonists
WO2015195634A1 (en)	2014-06-17	2015-12-23	Celgne Corporation	Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015195474A1 (en)	2014-06-18	2015-12-23	Biotheryx, Inc.	Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
GEP20197011B (en)	2014-06-19	2019-08-12	Ariad Pharma Inc	Heteroaryl compounds for kinase inhibition
MX2016014384A (es)	2014-06-23	2017-01-20	Celgene Corp	Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
EP3160486B1 (de)	2014-06-27	2020-11-18	Celgene Corporation	Zusammensetzungen und verfahren zur induktion von konformationsänderungen bei cereblon und anderen e3-ubiquitin-ligasen
US9499514B2 (en)	2014-07-11	2016-11-22	Celgene Corporation	Antiproliferative compounds and methods of use thereof
WO2016019368A1 (en)	2014-08-01	2016-02-04	The Brigham And Women's Hospital, Inc.	Methods and compositions relating to treatment of pulmonary arterial hypertension
WO2016025686A1 (en)	2014-08-15	2016-02-18	Celgene Corporation	Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
PL3182996T3 (pl)	2014-08-22	2023-04-17	Celgene Corporation	Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami
WO2016033555A1 (en)	2014-08-28	2016-03-03	Halozyme, Inc.	Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
JP2017526367A (ja)	2014-08-29	2017-09-14	チルドレンズメディカルセンターコーポレーション	癌の処置のための方法および組成物
US20170319548A1 (en)	2014-09-12	2017-11-09	Tobira Therapeutics, Inc.	Cenicriviroc combination therapy for the treatment of fibrosis
HRP20220651T1 (hr)	2014-09-15	2022-08-19	The Regents Of The University Of California	Nukleotidni analozi
JP7095990B2 (ja)	2014-09-18	2022-07-05	シーダーズ－サイナイメディカルセンター	線維症を治療するための組成物及び方法
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
JP6625627B2 (ja)	2014-10-14	2019-12-25	ハロザイムインコーポレイテッド	アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法
EP3206708B1 (de)	2014-10-16	2022-11-02	Cleveland Biolabs, Inc.	Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit strahlung
RS60737B1 (sr)	2014-10-21	2020-09-30	Ariad Pharma Inc	Kristalni oblici 5-hloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina
US20170354639A1 (en)	2014-10-24	2017-12-14	Biogen Ma Inc.	Diterpenoid derivatives and methods of use thereof
PT3215127T (pt)	2014-11-07	2021-02-10	Sublimity Therapeutics Ltd	Composições que compreendem ciclosporina
TW201702218A (zh)	2014-12-12	2017-01-16	美國杰克森實驗室	關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
BR112017012646A2 (pt)	2014-12-16	2018-01-02	Celgene Corporation	Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas
HUE049801T2 (hu)	2014-12-23	2020-10-28	Sma Therapeutics Inc	3,5-diaminopirazol kináz inhibitorok
US9676793B2 (en)	2014-12-23	2017-06-13	Hoffmann-Laroche Inc.	Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CN107530423B (zh)	2015-01-14	2022-04-05	布里格姆及妇女医院股份有限公司	用抗lap单克隆抗体治疗癌症
JP2018502889A (ja)	2015-01-20	2018-02-01	エックスオーシーファーマシューティカルズインコーポレイテッドＸｏｃＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ	イソエルゴリン化合物およびその使用
CA2974117A1 (en)	2015-01-20	2016-07-28	Xoc Pharmaceuticals, Inc.	Ergoline compounds and uses thereof
US11497733B2 (en)	2015-02-09	2022-11-15	Synta Pharmaceuticals Corp.	Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancer
CN107660207B (zh)	2015-03-10	2020-09-29	罗德科技公司	丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
TW201642857A (zh)	2015-04-06	2016-12-16	西建公司	以組合療法治療肝細胞癌
EP4194001A1 (de)	2015-04-22	2023-06-14	Cedars-Sinai Medical Center	Enterisch verabreichte bittere oligopeptide zur behandlung von typ-2-diabetes und fettleibigkeit
CN107922334B (zh)	2015-04-30	2021-11-23	科罗拉多大学董事会	多环吲哚啉和假吲哚化合物
CN108368147A (zh)	2015-05-27	2018-08-03	南方研究院	用于治疗癌症的核苷酸
EP3303286B1 (de)	2015-06-01	2023-10-04	Cedars-Sinai Medical Center	An rela von nf-kb anbindende verbindungen zur verwendung bei der behandlung von krebs
WO2016202721A1 (en)	2015-06-16	2016-12-22	F. Hoffmann-La Roche Ag	Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
AU2016282790B9 (en)	2015-06-23	2020-01-30	Neurocrine Biosciences, Inc.	VMAT2 inhibitors for treating neurological diseases or disorders
WO2016210262A1 (en)	2015-06-26	2016-12-29	Celgene Corporation	Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
CA2991164A1 (en)	2015-07-02	2017-01-05	Celgene Corporation	Combination therapy for treatment of hematological cancers and solid tumors
BR112018001441A2 (pt)	2015-07-28	2018-09-11	Vyome Biosciences Pvt Ltd	antibacterianos terapêuticos e profiláticos
WO2017023912A1 (en)	2015-08-03	2017-02-09	Temple University - Of The Commonwealth System Of Higher Education	2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
HUE057306T2 (hu)	2015-08-17	2022-04-28	Kura Oncology Inc	Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
JP2018530315A (ja)	2015-08-27	2018-10-18	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	疼痛の治療を目的とする組成物及び方法
CA2997947A1 (en)	2015-09-09	2017-03-16	The Trustees Of Columbia University In The City Of New York	Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
WO2017058828A1 (en)	2015-09-28	2017-04-06	Children's Hospital Los Angeles	Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
WO2017059385A1 (en)	2015-09-30	2017-04-06	Siteone Therapeutics, Inc.	11,13-modified saxitoxins for the treatment of pain
RU2022102624A (ru)	2015-10-01	2022-03-10	Хит Байолоджикс, Инк.	Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
WO2017069958A2 (en)	2015-10-09	2017-04-27	The Brigham And Women's Hospital, Inc.	Modulation of novel immune checkpoint targets
US20180312534A1 (en)	2015-10-16	2018-11-01	Invictus Oncology Pvt. Ltd.	Fluorescent anticancer platinum drugs
AU2016343633B2 (en)	2015-10-30	2021-07-01	Neurocrine Biosciences, Inc.	Valbenazine salts and polymorphs thereof
WO2017079566A1 (en)	2015-11-05	2017-05-11	Conatus Pharmaceuticals, Inc.	Caspase inhibitors for use in the treatment of liver cancer
CA3003969A1 (en)	2015-11-06	2017-05-11	Orionis Biosciences Nv	Bi-functional chimeric proteins and uses thereof
EP3373916A1 (de)	2015-11-11	2018-09-19	Celgene Corporation	Orale retard-darreichungsformen von schwer löslichen arzneimitteln und verwendungen davon
US10112924B2 (en)	2015-12-02	2018-10-30	Astraea Therapeutics, Inc.	Piperdinyl nociceptin receptor compounds
PT3394057T (pt)	2015-12-23	2022-04-21	Neurocrine Biosciences Inc	Método sintético para a preparação de 2-amino-3-metilbutanoato de di(4-metilbenzenesulfonato) (s)-(2r,3r,11br)-3-isobutil-9,10-dimetoxi-2,3,4,6,7,11bhexaidro-1h-pirido[2,1,-a]lsoquinolin-2-ilo
WO2017117118A1 (en)	2015-12-28	2017-07-06	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
JP2019500397A (ja)	2015-12-31	2019-01-10	クオナトウスファーマシューティカルズ，インコーポレイテッド	カスパーゼ阻害剤を肝疾患の治療に使用する方法
CN108712904B (zh)	2016-01-08	2022-08-02	细胞基因公司	2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
ES2957477T3 (es)	2016-01-08	2024-01-19	Celgene Corp	Compuestos antiproliferativos para usar en el tratamiento de leucemia
EP3399980A4 (de)	2016-01-08	2019-09-04	Celgene Corporation	Verfahren zur behandlung von krebs und verwendung von biomarkern als prädiktor klinischer empfindlichkeit gegenüber therapien
JP6991979B2 (ja)	2016-02-05	2022-03-04	オリオニスバイオサイエンシズビーブイ	Ｃｄ８結合物質
JP2019507181A (ja)	2016-03-04	2019-03-14	チャールストンラボラトリーズ，インコーポレイテッド	医薬組成物
US11248057B2 (en)	2016-03-07	2022-02-15	Vib Vzw	CD20 binding single domain antibodies
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CN108884019A (zh)	2016-04-11	2018-11-23	克雷西奥生物科技有限公司	氘代氯胺酮衍生物
US10047077B2 (en)	2016-04-13	2018-08-14	Skyline Antiinfectives, Inc.	Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190119758A1 (en)	2016-04-22	2019-04-25	Kura Oncology, Inc.	Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
WO2017190086A1 (en)	2016-04-29	2017-11-02	Fgh Biotech, Inc.	Di-substituted pyrazole compounds for the treatment of diseases
JP2019514960A (ja)	2016-05-04	2019-06-06	パーデューファーマエルピー	オキサゾリンシュードダイマー、医薬組成物及びその使用
EP3454887B1 (de)	2016-05-13	2021-01-20	Orionis Biosciences BV	Zielgerichtete mutanten-interferon-beta und verwendungen davon
CN109563141A (zh)	2016-05-13	2019-04-02	奥里尼斯生物科学公司	对非细胞结构的治疗性靶向
TWI753910B (zh)	2016-05-16	2022-02-01	美商拜歐斯瑞克斯公司	吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3484475B1 (de)	2016-07-18	2023-09-27	Pharmena S.A.	1-methylnicotinamid zur behandlung von cardiovaskulären erkrankungen
JOP20190008A1 (ar)	2016-07-26	2019-01-24	Purdue Pharma Lp	علاج ومنع اضطرابات النوم
EP3494119A4 (de)	2016-07-29	2020-03-25	Sunovion Pharmaceuticals Inc.	Verbindungen und zusammensetzungen und verwendungen davon
EP3490607A4 (de)	2016-07-29	2020-04-08	Sunovion Pharmaceuticals Inc.	Verbindungen und zusammensetzungen und verwendungen davon
CN110072861B (zh)	2016-09-07	2022-11-11	Fgh生物科技公司	用于治疗疾病的二取代吡唑类化合物
US10729670B2 (en)	2016-09-07	2020-08-04	Temple University—Of The Commonwealth Systems Of Higher Education	Compositions and methods for treatment of insulin resistance
AU2017326558B2 (en)	2016-09-19	2022-01-06	Mei Pharma, Inc.	Combination therapy
WO2018067991A1 (en)	2016-10-07	2018-04-12	The Brigham And Women's Hospital, Inc.	Modulation of novel immune checkpoint targets
WO2018069312A1 (en)	2016-10-11	2018-04-19	Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne)	Treatment of synucleinopathies
WO2018071814A1 (en)	2016-10-14	2018-04-19	The Trustees Of Columbia University In The City Of New York	Methods of treating alcohol abuse disorder
CN110072522A (zh)	2016-10-21	2019-07-30	美国大仁医疗有限公司	提高癌细胞对顺铂的敏感性的物质和方法
CA3040802A1 (en)	2016-10-24	2018-05-03	Orionis Biosciences Nv	Targeted mutant interferon-gamma and uses thereof
EA201991091A1 (ru)	2016-11-03	2019-11-29		Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы
AU2017397463B2 (en)	2016-11-03	2022-01-06	HedoniaUSA, Inc.	Compositions and methods for treating depression
US10106521B2 (en)	2016-11-09	2018-10-23	Phloronol, Inc.	Eckol derivatives, methods of synthesis and uses thereof
US10988442B2 (en)	2016-11-09	2021-04-27	Novomedix, Llc	Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
EP3548007A4 (de)	2016-12-01	2020-08-12	Ignyta, Inc.	Verfahren zur behandlung von krebs
US20200078352A1 (en)	2016-12-02	2020-03-12	Neurocrine Biosciences, Inc.	Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
WO2018140092A1 (en)	2017-01-27	2018-08-02	Obrien Christopher F	Methods for the administration of certain vmat2 inhibitors
WO2018140671A1 (en)	2017-01-27	2018-08-02	Celgene Corporation	3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
WO2018144999A1 (en)	2017-02-06	2018-08-09	Orionis Biosciences, Inc.	Targeted engineered interferon and uses thereof
US10889587B2 (en)	2017-02-06	2021-01-12	Spero Therapeutics, Inc.	Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
MX2019009255A (es)	2017-02-06	2019-11-05	Orionis Biosciences Nv	Proteínas quiméricas dirigidas y sus usos.
US11246911B2 (en)	2017-02-07	2022-02-15	Vib Vzw	Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2018151861A1 (en)	2017-02-16	2018-08-23	Sunovion Pharamaceuticials Inc.	Methods of treating schizophrenia
CN114796218A (zh)	2017-02-21	2022-07-29	库拉肿瘤学公司	使用法尼基转移酶抑制剂治疗癌症的方法
US9956215B1 (en)	2017-02-21	2018-05-01	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
US11192933B2 (en)	2017-02-27	2021-12-07	Shattuck Labs, Inc.	VSIG8-based chimeric proteins
WO2018164996A1 (en)	2017-03-06	2018-09-13	Neurocrine Biosciences, Inc.	Dosing regimen for valbenazine
WO2018165142A1 (en)	2017-03-07	2018-09-13	Celgene Corporation	Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP3601326A4 (de)	2017-03-20	2020-12-16	The Broad Institute, Inc.	Verbindungen und verfahren zur regulierung der insulinsekretion
CA3050086A1 (en)	2017-03-26	2018-10-04	Mapi Pharma Ltd.	Glatiramer depot systems for treating progressive forms of multiple sclerosis
WO2018183782A1 (en)	2017-03-29	2018-10-04	Siteone Therapeutics, Inc.	11,13-modified saxitoxins for the treatment of pain
CN110831945B (zh)	2017-03-29	2023-08-08	赛特温治疗公司	用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
WO2018200605A1 (en)	2017-04-26	2018-11-01	Neurocrine Biosciences, Inc.	Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar)	2017-05-09	2019-09-22	Cardix Therapeutics LLC	تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en)	2017-05-10	2018-10-02	Arixa Pharmaceuticals, Inc.	Beta-lactamase inhibitors and uses thereof
MX2019013561A (es)	2017-05-19	2022-02-09	Nflection Therapeutics Inc	Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
ES2913213T3 (es)	2017-05-19	2022-06-01	Nflection Therapeutics Inc	Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
EP3630079A4 (de)	2017-05-31	2021-02-24	The Children's Medical Center Corporation	Targeting von lysin-demethylasen (kdm) als therapeutische strategie für diffuses grosses b-zell-lymphom
CA3064274A1 (en)	2017-06-01	2018-12-06	Xoc Pharmaceuticals, Inc.	Ergoline derivatives for use in medicine
WO2019005874A1 (en)	2017-06-26	2019-01-03	The Trustees Of Columbia University In The City Of New York	CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
WO2019014398A1 (en)	2017-07-11	2019-01-17	Actym Therapeutics, Inc.	MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
CA3069462A1 (en)	2017-07-16	2019-01-24	Neuere, Llc	Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
EP3661929B1 (de)	2017-08-02	2021-07-14	Sunovion Pharmaceuticals Inc.	Isochromanverbindungen und verwendungen davon
SG11202000894TA (en)	2017-08-07	2020-02-27	Kura Oncology Inc	Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en)	2017-08-07	2020-10-20	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
AU2018335259A1 (en)	2017-09-21	2020-04-09	Neurocrine Biosciences, Inc.	High dosage valbenazine formulation and compositions, methods, and kits related thereto
AU2017435893B2 (en)	2017-10-10	2023-06-29	Neurocrine Biosciences, Inc	Methods for the administration of certain VMAT2 inhibitors
US10993941B2 (en)	2017-10-10	2021-05-04	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
EP3713916A1 (de)	2017-11-20	2020-09-30	Kiakos, Konstantinos	Aus 3,5-diarylidenyl-n-substituiertes-piperid-4-on abgeleitete inhibitoren der stat3-weg-aktivität und verwendungen davon
WO2019113269A1 (en)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019118984A2 (en)	2017-12-15	2019-06-20	Solarea Bio, Inc.	Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
WO2019126136A2 (en)	2017-12-18	2019-06-27	Sterngreene, Inc.	Pyrimidine compounds useful as tyrosine kinase inhibitors
WO2019136314A1 (en)	2018-01-05	2019-07-11	The Curators Of The University Of Missouri	Compounds and methods for treatment of cystic fibrosis
TW201929847A (zh)	2018-01-10	2019-08-01	美商克拉治療有限責任公司	包含二羧酸之醫藥組合物及其治療應用
WO2019139869A1 (en)	2018-01-10	2019-07-18	Cura Therapeutics Llc	Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
KR20200103045A (ko)	2018-01-24	2020-09-01	퍼듀 퍼머 엘피	수면 장애 치료 및 예방
EP3749295A4 (de)	2018-02-05	2022-04-27	Orionis Biosciences, Inc.	Fibroblastenbindende wirkstoffe und verwendung davon
KR20200141986A (ko)	2018-02-12	2020-12-21	다이어비티스-프리, 인크.	개선된 길항성 항-인간 cd40 단클론 항체
US20210008030A1 (en)	2018-02-16	2021-01-14	Sunovion Pharmaceuticals Inc.	Methods of treating social function disorders
KR20200138714A (ko)	2018-02-21	2020-12-10	에이아이 테라퓨틱스, 인코포레이티드	아필리모드 및 글루타메이트성 작용제를 사용한 병용 요법
US20210015899A1 (en)	2018-03-22	2021-01-21	The Children's Medical Center Corporation	Methods and compositions relating to lung repair
US20190351031A1 (en)	2018-05-16	2019-11-21	Halozyme, Inc.	Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2019241555A1 (en)	2018-06-14	2019-12-19	Neurocrine Biosciences, Inc.	Vmat2 inhibitor compounds, compositions, and methods relating thereto
US11447497B2 (en)	2018-06-29	2022-09-20	Histogen, Inc.	(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
CA3106143A1 (en)	2018-07-11	2020-01-16	Actym Therapeutics, Inc.	Engineered immunostimulatory bacterial strains and uses thereof
AU2019322863A1 (en)	2018-08-15	2021-03-11	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
WO2020047161A2 (en)	2018-08-28	2020-03-05	Actym Therapeutics, Inc.	Engineered immunostimulatory bacterial strains and uses thereof
JP2022511286A (ja)	2018-08-29	2022-01-31	シャタックラボ，インコーポレイテッド	Ｓｉｒｐアルファ系キメラタンパク質を含む併用療法
CA3111795A1 (en)	2018-09-05	2020-03-12	Solarea Bio, Inc.	Methods and compositions for treating musculoskeletal diseases
EP3860714B1 (de)	2018-10-03	2023-09-06	Siteone Therapeutics, Inc.	11,13-modifizierte saxitoxine zur behandlung von schmerzen
SG11202104296TA (en)	2018-11-01	2021-05-28	Kura Oncology Inc	Methods of treating cancer with farnesyltransferase inhibitors
WO2020102454A1 (en)	2018-11-13	2020-05-22	Regents Of The University Of Minnesota	Cd40 targeted peptides and uses thereof
JP7406264B2 (ja)	2018-11-20	2023-12-27	エヌフレクションセラピューティクスインコーポレイテッド	皮膚障害の処置のためのシアノアリール－アニリン化合物
EP4233865A3 (de)	2018-11-20	2023-09-27	NFlection Therapeutics, Inc.	Aryl-anilin- und heteroaryl-anilinverbindungen zur behandlung von hautkrebs
MA55144A (fr)	2018-11-20	2021-09-29	Nflection Therapeutics Inc	Composés naphthyridinone-aniline destinés au traitement d'affections de la peau
CN113645964A (zh)	2018-11-20	2021-11-12	恩福莱克逊治疗有限公司	用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
US20230078755A1 (en)	2018-12-19	2023-03-16	Shy Therapeutics, Llc	Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
US20220071941A1 (en)	2018-12-21	2022-03-10	Kura Oncology, Inc.	Therapies for squamous cell carcinomas
WO2020132700A1 (en)	2018-12-21	2020-06-25	Fgh Biotech Inc.	Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
CN113874080A (zh)	2019-02-06	2021-12-31	戴斯阿尔法公司	Il-17a调节剂及其用途
CN113748124A (zh)	2019-02-27	2021-12-03	阿克蒂姆治疗有限公司	工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌
WO2020180663A1 (en)	2019-03-01	2020-09-10	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
JP2022524049A (ja)	2019-03-07	2022-04-27	クオナトウスファーマシューティカルズ，インコーポレイテッド	カスパーゼ阻害剤及びその使用方法
CA3130849A1 (en)	2019-03-14	2020-09-17	Sunovion Pharmaceuticals Inc.	Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US20220143006A1 (en)	2019-03-15	2022-05-12	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2020193431A1 (en)	2019-03-22	2020-10-01	Deutsches Krebsforschungszentrum	Novel inhibitors of histone deacetylase 10
EP3712127A1 (de)	2019-03-22	2020-09-23	Deutsches Krebsforschungszentrum	Neuartige inhibitoren der histon-deacetylase 10
CA3134825A1 (en)	2019-03-29	2020-10-08	Kura Oncology, Inc.	Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
WO2020205387A1 (en)	2019-04-01	2020-10-08	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
JP2022527825A (ja)	2019-04-03	2022-06-06	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	薬物送達のためのイオン液体
US20220305001A1 (en)	2019-05-02	2022-09-29	Kura Oncology, Inc.	Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CN113874375A (zh)	2019-06-03	2021-12-31	株式会社大分大学先端医学研究所	用于治疗狂犬病的环状酰胺化合物及其方法
EP3986163A2 (de)	2019-06-19	2022-04-27	Solarea Bio, Inc.	Mikrobielle zusammensetzungen und verfahren zur herstellung von aufgewerteten probiotischen zusammenstellungen
CA3146159A1 (en)	2019-07-11	2021-01-14	Cura Therapeutics, Llc	Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
US20220274922A1 (en)	2019-07-11	2022-09-01	Cura Therapeutics, Llc	Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP4003314A4 (de)	2019-07-26	2023-09-20	Espervita Therapeutics, Inc.	Funktionalisierte langkettige kohlenwasserstoffmono- und -dicarbonsäuren zur vorbeugung oder behandlung von krankheiten
US10792262B1 (en)	2019-07-29	2020-10-06	Saol International Limited	Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en)	2019-07-29	2023-05-23	Amneal Pharmaceuticals Llc	Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10940141B1 (en)	2019-08-23	2021-03-09	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
CN115551530A (zh)	2019-08-27	2022-12-30	通尼克斯制药有限公司	经修饰的tff2多肽
IL291345B2 (en)	2019-09-16	2024-04-01	Dice Alpha Inc	IL-17A modulators and uses thereof
WO2021059023A1 (en)	2019-09-26	2021-04-01	Abionyx Pharma Sa	Compounds useful for treating liver diseases
KR20220091488A (ko)	2019-10-01	2022-06-30	몰레큘러 스킨 테라퓨틱스, 인코포레이티드	Klk5/7 이중 억제제로서의 벤족사지논 화합물
IL292836A (en)	2019-11-12	2022-07-01	Actym Therapeutics Inc	Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products
AU2020388387A1 (en)	2019-11-22	2022-06-02	President And Fellows Of Harvard College	Ionic liquids for drug delivery
JP2023505150A (ja)	2019-12-02	2023-02-08	セルジーンコーポレーション	がんの処置のための治療法
US20230093147A1 (en)	2020-03-09	2023-03-23	President And Fellows Of Harvard College	Methods and compositions relating to improved combination therapies
TW202206062A (zh)	2020-04-24	2022-02-16	美國坦普大學高等教育聯邦系統	治療非酒精性脂肪肝炎的方法
EP4142787A1 (de)	2020-04-28	2023-03-08	President And Fellows Of Harvard College	Verfahren und zusammensetzungen in zusammenhang mit ionischen flüssigkeitsadjuvantien
WO2021226033A1 (en)	2020-05-07	2021-11-11	President And Fellows Of Harvard College	Hyaluronic acid drug conjugates
EP4157923A2 (de)	2020-05-29	2023-04-05	President And Fellows Of Harvard College	Mit polyphenolfunktionalisierten biologisch aktiven nanokomplexen manipulierte lebende zellen
US11529331B2 (en)	2020-05-29	2022-12-20	Boulder Bioscience Llc	Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
EP4168414A1 (de)	2020-06-18	2023-04-26	Shy Therapeutics LLC	Substituierte thienopyrimidine zur interaktion mit der ras-superfamilie zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
US20230102840A1 (en)	2020-06-23	2023-03-30	President And Fellows Of Harvard College	Compositions and methods relating to combinatorial hyaluronic acid conjugates
US11319313B2 (en)	2020-06-30	2022-05-03	Poxel Sa	Crystalline forms of deuterium-enriched pioglitazone
WO2022008976A1 (en)	2020-07-10	2022-01-13	Institut Pasteur	Use of gdf11 to diagnose and treat anxiety and depression
EP4196139A2 (de)	2020-08-12	2023-06-21	Actym Therapeutics, Inc.	Impfstoffe auf der basis von immunstimulierenden bakterien, therapeutika und rna-freisetzungsplattformen
CA3188924A1 (en)	2020-08-14	2022-02-17	Hassan Pajouhesh	Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
US11541009B2 (en)	2020-09-10	2023-01-03	Curemark, Llc	Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US20220133669A1 (en)	2020-10-30	2022-05-05	Ds Biopharma Limited	Pharmaceutical compositions comprising 15-hetre and methods of use thereof
WO2022155410A1 (en)	2021-01-15	2022-07-21	President And Fellows Of Harvard College	Methods and compositions relating to anti-mfsd2a antibodies
US20240115607A1 (en)	2021-01-26	2024-04-11	Cytocares (Shanghai) Inc.	Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
EP4284377A1 (de)	2021-01-27	2023-12-06	Shy Therapeutics LLC	Verfahren zur behandlung von fibrotischen erkrankungen
WO2022165000A1 (en)	2021-01-27	2022-08-04	Shy Therapeutics, Llc	Methods for the treatment of fibrotic disease
WO2022187573A1 (en)	2021-03-05	2022-09-09	President And Fellows Of Harvard College	Methods and compositions relating to cell membrane hybridization and camouflaging
WO2022189010A1 (en)	2021-03-07	2022-09-15	Givaudan Sa	Methods and compositions for treating and preventing urinary tract infections
WO2022189856A1 (en)	2021-03-08	2022-09-15	Abionyx Pharma Sa	Compounds useful for treating liver diseases
BR112023018290A2 (pt)	2021-03-10	2023-12-12	Dice Molecules Sv Inc	Inibidores da integrina alfa v beta 6 e alfa v beta 1 e usos dos mesmos
CN117083071A (zh)	2021-03-19	2023-11-17	蒂巴生物技术有限公司	人工甲病毒衍生的rna复制子表达系统
WO2022226166A1 (en)	2021-04-22	2022-10-27	Protego Biopharma, Inc.	Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
WO2022251533A1 (en)	2021-05-27	2022-12-01	Protego Biopharma, Inc.	Heteroaryl diamide ire1/xbp1s activators
WO2022265880A1 (en)	2021-06-16	2022-12-22	President And Fellows Of Harvard College	Improved methods and compositions for drug delivery relating to ionic liquids
WO2022271537A1 (en)	2021-06-25	2022-12-29	President And Fellows Of Harvard College	Compositions and methods relating to injectable microemulsions
KR20240044458A (ko)	2021-08-05	2024-04-04	브리스톨-마이어스 스큅 컴퍼니	Her2 억제제로서 사용하기 위한 트리시클릭 융합된 피리미딘 화합물
WO2023034506A1 (en)	2021-09-01	2023-03-09	Flagship Pioneering Innovations Vi, Llc	Methods and compositions for inducing fetal hemoglobin
US20230083717A1 (en)	2021-09-01	2023-03-16	Flagship Pioneering Innovations Vi, Llc	Methods and compositions for promoting adipocyte beiging
WO2023034507A1 (en)	2021-09-01	2023-03-09	Flagship Pioneering Innovations Vi, Llc	In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
WO2023034504A1 (en)	2021-09-01	2023-03-09	Flagship Pioneering Innovations Vi, Llc	Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
US20230077584A1 (en)	2021-09-09	2023-03-16	Flagship Pioneering Innovations Vi, Llc	Methods and compositions for modulating enteroendocrine cells
WO2023039164A2 (en)	2021-09-09	2023-03-16	Flagship Pioneering Innovations Vi, Llc	Methods and compositions for modulating goblet cells and for muco-obstructive diseases
WO2023043827A2 (en)	2021-09-14	2023-03-23	Flagship Pioneering Innovations Vi, Llc	Methods and compositions for perturbing monocyte and neutrophil lineages
WO2023055457A1 (en)	2021-09-29	2023-04-06	Amneal Pharmaceuticals Llc	Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
CA3233824A1 (en)	2021-10-08	2023-04-13	Samir Mitragotri	Ionic liquids for drug delivery
EP4162933A1 (de)	2021-10-08	2023-04-12	Algiax Pharmaceuticals GmbH	Verbindung zur behandlung von nicht-alkoholischer fettlebererkrankung und verwandten erkrankungen
WO2023076997A1 (en)	2021-10-28	2023-05-04	Zywie, Llc	Modified forms of ambroxol for therapeutic use
WO2023092150A1 (en)	2021-11-22	2023-05-25	Solarea Bio, Inc.	Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
TW202327590A (zh)	2021-11-30	2023-07-16	美商庫拉腫瘤技術股份有限公司	大環化合物及組合物以及其製備及使用方法
US20230190834A1 (en)	2021-12-21	2023-06-22	Solarea Bio, Inc.	Immunomodulatory compositions comprising microbial entities
WO2023129577A1 (en)	2022-01-03	2023-07-06	Lilac Therapeutics, Inc.	Cyclic thiol prodrugs
WO2023168426A1 (en)	2022-03-03	2023-09-07	Enosi Therapeutics Corporation	Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2023192817A1 (en)	2022-03-28	2023-10-05	Isosterix, Inc.	Inhibitors of the myst family of lysine acetyl transferases
TW202342070A (zh)	2022-03-30	2023-11-01	美商拜奧馬林製藥公司	肌萎縮蛋白外顯子跳躍寡核苷酸
GB2619907A (en)	2022-04-01	2023-12-27	Kanna Health Ltd	Novel crystalline salt forms of mesembrine
US20230331693A1 (en)	2022-04-14	2023-10-19	Bristol-Myers Squibb Company	Gspt1 compounds and methods of use of the novel compounds
WO2023201348A1 (en)	2022-04-15	2023-10-19	Celgene Corporation	Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2023211990A1 (en)	2022-04-25	2023-11-02	Siteone Therapeutics, Inc.	Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2023215781A1 (en)	2022-05-05	2023-11-09	Biomarin Pharmaceutical Inc.	Method of treating duchenne muscular dystrophy
WO2023230524A1 (en)	2022-05-25	2023-11-30	Flagship Pioneering Innovations Vi, Llc	Compositions of secretory and/or catalytic cells and methods using the same
WO2024054832A1 (en)	2022-09-09	2024-03-14	Innovo Therapeutics, Inc.	CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
WO2024073473A1 (en)	2022-09-30	2024-04-04	Boulder Bioscience Llc	Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1572137A (en) *	1977-02-22	1980-07-23	Bioresearch Sas Del Dr Livio C	Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
DE2832009A1 (de) *	1978-07-20	1980-01-31	Deutsches Krebsforsch	Verwendung von sarkosin und sarkosinderivaten ls tumorhemmende wirksubstanzen
JPS5618982A (en) *	1979-06-14	1981-02-23	Wellcome Found	Pyrimidine derivatives and medicinal drug containing them
GB2072504B (en) *	1980-03-27	1983-10-26	Coppen A J	Pharmaceutical compositions
US4369172A (en) *	1981-12-18	1983-01-18	Forest Laboratories Inc.	Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4619913A (en) *	1984-05-29	1986-10-28	Matrix Pharmaceuticals, Inc.	Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4550109A (en) *	1984-05-31	1985-10-29	The Board Of Regents, The University Of Texas System	Lipoidal biopterin compounds
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4585652A (en) *	1984-11-19	1986-04-29	Regents Of The University Of Minnesota	Electrochemical controlled release drug delivery system
US4826817A (en) *	1986-02-07	1989-05-02	Brown Thomas E	Amino acid and hydroxyamino acid transporter compounds for therapeutic applications, process and use
US4812449A (en) *	1986-07-03	1989-03-14	Scripps Clinic And Research Foundation	In situ active compound assembly
GB8625019D0 (en) *	1986-10-18	1986-11-19	Wellcome Found	Compounds
GB8702758D0 (en) *	1987-02-06	1987-03-11	Wellcome Found	Treatment of disease
IT1204612B (it) *	1987-05-14	1989-03-10	Bioresearch Spa	Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
US4940713A (en) *	1988-04-15	1990-07-10	Burroughs Wellcome Co.	Substituted glutamic acids
US4921836A (en) *	1989-05-17	1990-05-01	Burroughs Wellcome Co.	Substituted glutamic acids

1989
- 1989-03-22 IT IT8919867A patent/IT1229203B/it active
1990
- 1990-03-19 ES ES90105095T patent/ES2062141T3/es not_active Expired - Lifetime
- 1990-03-19 DK DK90105095.5T patent/DK0388827T3/da active
- 1990-03-19 EP EP90105095A patent/EP0388827B1/de not_active Expired - Lifetime
- 1990-03-19 DE DE90105095T patent/DE69004837T2/de not_active Expired - Lifetime
- 1990-03-19 AT AT90105095T patent/ATE97809T1/de not_active IP Right Cessation
- 1990-03-20 ZA ZA902153A patent/ZA902153B/xx unknown
- 1990-03-20 US US07/496,366 patent/US5059595A/en not_active Expired - Lifetime
- 1990-03-21 AU AU52092/90A patent/AU637086B2/en not_active Ceased
- 1990-03-22 JP JP2073156A patent/JPH0791190B2/ja not_active Expired - Lifetime
- 1990-03-22 CA CA002012876A patent/CA2012876C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH0791190B2 (ja)	1995-10-04
IT1229203B (it)	1991-07-25
EP0388827A1 (de)	1990-09-26
DE69004837T2 (de)	1994-04-07
JPH02289517A (ja)	1990-11-29
ZA902153B (en)	1990-12-28
IT8919867A0 (it)	1989-03-22
US5059595A (en)	1991-10-22
AU5209290A (en)	1990-09-27
ES2062141T3 (es)	1994-12-16
ATE97809T1 (de)	1993-12-15
AU637086B2 (en)	1993-05-20
EP0388827B1 (de)	1993-12-01
DK0388827T3 (da)	1994-03-21
CA2012876C (en)	2001-02-13
CA2012876A1 (en)	1990-09-22

Legal Events

Date	Code	Title	Description
1995-01-05	8364	No opposition during term of opposition
2001-02-22	8327	Change in the person/name/address of the patent owner	Owner name: KNOLL FARMACEUTICI S.P.A., MUGGIO, MAILAND/MILANO,
2003-07-10	8327	Change in the person/name/address of the patent owner	Owner name: KNOLL-RAVIZZA FARMACEUTICI S.P.A., CAMPOVERDE DI A

Publication	Publication Date	Title
DE69004837D1 (de)	1994-01-13	Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel.
ATE88895T1 (de)	1993-05-15	Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.
IL104006A (en)	1997-02-18	Azaheterocyclylmethyl-chromans their preparation and pharmaceutical compositions containing them
ATE231885T1 (de)	2003-02-15	Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura
HU9401445D0 (en)	1994-08-29	Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
DE3876877T2 (de)	1993-04-29	Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ATE290385T1 (de)	2005-03-15	Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten
ATE184485T1 (de)	1999-10-15	Verwendung der 1-4-4-aryl(oder heteroaryl)-1- piperazinylbutyl-1h-azol-derivate zur herstellung von arzneimitteln zur behandlung der störungen der magensekretion
DE69005557T2 (de)	1994-04-21	Substituierte 4-Amino-2-butinyl-Harnstoffe und -thioharnstoffe sowie deren Derivate als zentral wirkende muscarinische Mittel.
ATE169500T1 (de)	1998-08-15	Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen
NZ245380A (en)	1994-06-27	Piperidylmethyl-substituted chroman derivatives, preparation and pharmaceutical compositions thereof
ATE402253T1 (de)	2008-08-15	Humane adulte astrozyten, sowie deren herstellung und verwendung
NO169391C (no)	1992-06-17	Analogifremgangsmaate for fremstilling av et terapeutisk aktivt (-)-cis-quinuklidin og syreaddisjonssalter derav
ES2009689A6 (es)	1989-10-01	Procedimiento para preparar derivados de 3-piperidina-carbaldehido-oxima.
NZ292388A (en)	1999-03-29	S-enantiomers of 2-alkyl substituted pentynoic acid derivatives, preparation and pharmaceutical compositions thereof
HU9202229D0 (en)	1992-10-28	Method for manufacturing new pharmaceutical preparatives containing 2-oxo-benzimidaazoline-1-carboxylic acid derivatives
DE69434002D1 (de)	2004-10-21	2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
HUT61469A (en)	1993-01-28	Process for producing pharmaceutical composition with nervous system effects
DE69009765D1 (de)	1994-07-14	Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DK0950053T3 (da)	2003-09-29	Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater
ATE192336T1 (de)	2000-05-15	Verwendung von bifemelan zur herstellung eines arzneimittels zur behandlung der hyperkinesie
ATE205499T1 (de)	2001-09-15	Heterocyclische verbindungen, deren herstellung und verwendung